{"gene":"GCGR","run_date":"2026-04-28T18:06:52","timeline":{"discoveries":[{"year":1994,"finding":"The human glucagon receptor (GCGR) was cloned from a liver cDNA library; it encodes a 477-amino-acid seven-transmembrane G protein-coupled receptor that, when transfected into COS-7 cells, confers high-affinity [125I]glucagon binding and transduces signals leading to increases in intracellular cAMP. Rank-order potency of binding: glucagon > oxyntomodulin > GLP-1(7-36) amide >> GLP-2 = GIP = secretin.","method":"cDNA cloning, heterologous expression in COS-7 cells, radioligand binding assay, cAMP measurement","journal":"Biochemical and Biophysical Research Communications","confidence":"High","confidence_rationale":"Tier 1 — functional receptor reconstitution in heterologous cells with ligand binding and cAMP signaling validated; foundational cloning paper","pmids":["7507321"],"is_preprint":false},{"year":1994,"finding":"The GCGR gene maps to human chromosome 17q25, spans >5.5 kb with 12 introns, and encodes a receptor with 80% identity to rat GCGR. The cDNA-expressed receptor binds glucagon and signals via intracellular cAMP elevation.","method":"cDNA cloning from liver library, Southern blot, in situ hybridization to metaphase chromosomes, cAMP assay","journal":"Gene","confidence":"High","confidence_rationale":"Tier 1 — direct genomic characterization and functional validation in expressing cells","pmids":["8144028"],"is_preprint":false},{"year":1995,"finding":"A missense mutation Gly40Ser in GCGR is associated with NIDDM; receptor binding studies in cultured cells expressing this mutant show approximately three-fold lower glucagon-binding affinity compared to wild-type, establishing a functional consequence of this variant.","method":"Site-directed mutagenesis, radioligand binding assay in transfected cells, genetic association study","journal":"Nature Genetics","confidence":"High","confidence_rationale":"Tier 1-2 — direct functional binding assay in expressing cells combined with genetic association; replicated in disease context","pmids":["7773293"],"is_preprint":false},{"year":2003,"finding":"Three distinct epitopes on the extracellular face of the GCGR transmembrane core domain (at extracellular ends of TM2 and TM7, and the second extracellular loop/proximal TM4-TM5) determine specificity for the N-terminus of glucagon (residues Ser2, Gln3, Tyr10, Lys12). The N-terminal extracellular domain (ECD) determines specificity for the glucagon C-terminus, establishing a two-site binding model.","method":"Site-directed mutagenesis of receptor core domain, chimeric receptor construction, radioligand binding, cAMP functional assay","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with multiple orthogonal readouts defining specific receptor-ligand contacts","pmids":["12724331"],"is_preprint":false},{"year":2003,"finding":"Glucagon acting through GCGR promotes hepatic glucose output by stimulating glycogenolysis and gluconeogenesis, and inhibiting glycogenesis and glycolysis. In diabetic states, hyperglucagonemia and altered insulin-to-glucagon ratios contribute to hyperglycemia through excessive hepatic glucose production via GCGR.","method":"In vivo animal models and human physiological studies (review synthesizing mechanistic data)","journal":"American Journal of Physiology. Endocrinology and Metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — synthesis of established in vivo mechanistic studies; role in hepatic glucose regulation well established across multiple experimental systems","pmids":["12626323"],"is_preprint":false},{"year":2013,"finding":"Crystal structure of the seven-transmembrane helical domain of human GCGR resolved at 3.4 Å. The structure reveals a large ligand-binding pocket and a unique 'stalk' region extending three alpha-helical turns above the membrane plane on TM1, which positions the extracellular domain (~12 kDa) to form the glucagon-binding site. The ECD facilitates capture of glucagon peptide, enabling insertion of the glucagon N-terminus into the 7TM domain. Extensive site-specific mutagenesis and a hybrid glucagon-bound GCGR model provided molecular details of ligand recognition.","method":"X-ray crystallography (3.4 Å), site-directed mutagenesis, hybrid structural modeling","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus extensive mutagenesis; foundational structural paper replicated and extended by subsequent structures","pmids":["23863937"],"is_preprint":false},{"year":2013,"finding":"Oxyntomodulin activates both GCGR and GLP-1R; simultaneous activation of both receptors reduces food intake and increases energy expenditure, with GLP-1R agonism counteracting the hyperglycemic effect of GCGR activation. This dual mechanism results in superior body weight lowering compared to selective GLP-1R agonism.","method":"In vivo pharmacological studies; human infusion studies; cell-based cAMP assays","journal":"Molecular Metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pharmacology studies in vivo and in vitro across multiple groups","pmids":["24749050"],"is_preprint":false},{"year":2015,"finding":"Full-length GCGR can adopt open and closed conformations involving extensive contacts between the ECD and 7TM domain. Molecular dynamics and disulfide crosslinking studies indicate that apo-GCGR exists in both conformations, and peptide ligand binding (plus a monoclonal antibody) stabilizes an open/elongated conformation consistent with a conformational selection mechanism for glucagon binding. HDX studies identified the stalk and first extracellular loop as key modulators of peptide binding.","method":"Molecular dynamics simulations, disulfide crosslinking, electron microscopy, hydrogen/deuterium exchange (HDX), crystal structure of TMD","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (MD, crosslinking, EM, HDX) in single study with functional validation","pmids":["26227798"],"is_preprint":false},{"year":2015,"finding":"Loss-of-function GCGR germline mutations (including homozygous stop mutations and compound heterozygous missense mutations) cause glucagon cell adenomatosis (GCA) — multifocal hyperplastic/neoplastic disease of pancreatic glucagon cells. By interrupting GCGR signaling, mutations drive glucagon cell hyperplasia and neoplasia, with mutation carriers exhibiting greater numbers and larger tumors than wild-type patients.","method":"Sanger and next-generation sequencing of all GCGR exons, clinicopathological correlation, genotyping in 2560 controls","journal":"The Journal of Clinical Endocrinology and Metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function mutations with defined cellular phenotype (glucagon cell hyperplasia/neoplasia); mechanistic link to interrupted GCGR signaling established","pmids":["25695890"],"is_preprint":false},{"year":2016,"finding":"The small-molecule GCGR antagonist MK-0893 binds to an allosteric extra-helical site located between TM6 and TM7 extending into the lipid bilayer, outside the canonical 7TM bundle. This binding prevents the outward movement of TM6 required for G-protein coupling, thereby blocking receptor activation. Key residues at this novel site were confirmed by mutagenesis.","method":"X-ray crystallography (2.5 Å resolution of GCGR-MK-0893 complex), site-directed mutagenesis, functional cAMP assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure plus mutagenesis confirming allosteric binding site and mechanism of inhibition","pmids":["27111510"],"is_preprint":false},{"year":2016,"finding":"The ECD of GCGR is strictly required for receptor activation even when the peptide hormone is covalently linked to the TMD, unlike some other class B GPCRs (e.g., CRF1R, PTH1R, PAC1R) where ECD requirement can be bypassed. This demonstrates that the GCGR ECD plays a direct, active role in signaling beyond merely serving as an affinity trap.","method":"Chimeric receptor construction, covalent peptide-TMD linkage experiments, cAMP functional assays","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — direct mechanistic experiment with covalent tethering and functional assays establishing active role of ECD","pmids":["27226600"],"is_preprint":false},{"year":2017,"finding":"Crystal structure of full-length GCGR at 3.0 Å in inactive conformation reveals the stalk connecting the ECD and TMD adopts a β-strand conformation (not α-helix). The first extracellular loop (ECL1) forms a β-hairpin that interacts with the stalk to create a compact β-sheet structure. HDX, disulfide crosslinking and MD studies demonstrate that the stalk and ECL1 have critical roles in modulating peptide ligand binding and receptor activation.","method":"X-ray crystallography (3.0 Å, full-length), hydrogen-deuterium exchange, disulfide crosslinking, molecular dynamics","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — full-length crystal structure plus multiple orthogonal mechanistic validation methods","pmids":["28514451"],"is_preprint":false},{"year":2018,"finding":"Crystal structure of full-length GCGR in complex with glucagon analogue NNC1702 at 3.0 Å reveals the molecular details of peptide-receptor interactions. The stalk and ECL1 undergo major conformational changes (secondary structure rearrangements) during peptide binding, forming key contacts with the peptide. The ECD-TMD relative orientation changes markedly relative to the inactive structure. A 'dual-binding-site trigger model' is proposed for GCGR activation requiring conformational changes in the stalk, ECL1, and TMD.","method":"X-ray crystallography (3.0 Å, full-length GCGR-peptide complex), structural comparison","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure of active-state ligand complex defining molecular activation mechanism","pmids":["29300013"],"is_preprint":false},{"year":2011,"finding":"Complete ablation of hepatic glucagon receptor function in Gcgr-/- mice causes major metabolic alterations: significant down-regulation of gluconeogenesis, amino acid catabolism, and fatty acid oxidation, with up-regulation of glycolysis, fatty acid synthesis, and cholesterol biosynthesis. Plasma metabolite changes include decreased glucose and glucose-derived metabolites, and increased amino acids, cholesterol, and bile acids.","method":"Global Gcgr knockout mouse model, liver transcriptomics (Affymetrix arrays), liver proteomics (iTRAQ), plasma metabolite profiling (~200 analytes, mass spectrometry), pathway analysis","journal":"BMC Genomics","confidence":"High","confidence_rationale":"Tier 1-2 — genetic knockout with tri-omic profiling providing comprehensive mechanistic pathway placement; strong evidence from multiple orthogonal datasets","pmids":["21631939"],"is_preprint":false},{"year":2012,"finding":"GRA1, a small-molecule GCGR antagonist, blocks glucagon binding to human GCGR and antagonizes glucagon-induced cAMP accumulation with nanomolar potency. It inhibits glycogenolysis in primary human hepatocytes and perfused liver from humanized GCGR mice. In monkeys, GRA1 treatment down-regulates hepatic genes involved in amino acid catabolism and increases circulating amino acids, demonstrating GCGR's role in hepatic amino acid metabolism.","method":"In vitro cAMP assay, radioligand competition binding, primary human hepatocyte glycogenolysis assay, perfused liver from hGCGR transgenic mice, in vivo glucose tolerance in rodents and primates, hepatic gene-expression profiling","journal":"PLoS One","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal in vitro and in vivo methods in humanized model and primates; mechanistic link to amino acid metabolism established","pmids":["23185367"],"is_preprint":false},{"year":2018,"finding":"In Gcgr-/- mice, GLP-2 receptor (GLP-2R) signaling controls circulating bile acid levels and their relative species proportions but is not essential for body weight control or glucose homeostasis. Gpbar1 (TGR5) does not mediate elevated proglucagon-derived peptide levels or major metabolic phenotypes in Gcgr-/- mice despite elevated bile acids. Small bowel growth in Gcgr-/- mice requires intact GLP-2R signaling.","method":"Double-knockout mouse models (Gcgr-/-:Gpbar1-/-, Gcgr-/-:Glp2r-/-), glucose tolerance testing, insulin measurement, bile acid profiling, intestinal mass measurement","journal":"Molecular Metabolism","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis via double-knockout mice with multiple metabolic phenotypic readouts","pmids":["29937214"],"is_preprint":false},{"year":2020,"finding":"Computational free-energy landscape analysis reveals that GCGR activation follows a combined mechanism: the agonist (glucagon) first stabilizes the receptor in a 'pre-activated' state, which is then fully activated upon G protein binding — contrasting with the classical model of agonist-driven TM6 opening. This mechanism is consistent with cryo-EM structural data.","method":"Free-energy landscape computation (molecular dynamics simulations), comparison with cryo-EM structural data","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 1 — computational with structural validation, but single study; mechanistic model not yet confirmed by independent mutagenesis","pmids":["32571939"],"is_preprint":false},{"year":2020,"finding":"Cryo-EM structures of GCGR bound to glucagon in complex with either Gs or Gi1 heterotrimeric G proteins reveal that both Gs and Gi1 bind in a similar open intracellular cavity. GCGR's Gs-binding selectivity is explained by a larger interaction interface with Gs; specific intracellular loop conformational differences are key selectivity determinants. Mutagenesis of identified residues confirmed their roles in transducer engagement.","method":"Cryo-electron microscopy structural determination, site-directed mutagenesis, functional G protein coupling assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structures of two distinct GCGR-G protein complexes plus mutagenesis validation","pmids":["32193322"],"is_preprint":false},{"year":2021,"finding":"Glucagon potentiates glucose-stimulated insulin secretion (GSIS) via β-cell GCGR at physiological but not high glucose concentrations. GCGR activation elevates cAMP via adenylyl cyclase 5 (AC5) in β-cells, independently of high-glucose-induced cAMP elevation via the same AC5. High glucose concentration bypasses the GCGR requirement for cAMP elevation and insulin secretion. β-cell-specific GCGR knockout mice develop more severe glucose intolerance on high-fat diet.","method":"GCGR/GLP-1R antagonists in single β-cells, α-β cell clusters, and isolated islets; RAB-ICUE cAMP fluorescence indicator; specific AC family inhibitors; β-cell-specific GCGR knockout mice; high-fat diet metabolic phenotyping","journal":"Cells","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (live-cell imaging, pharmacological inhibition, cell-specific knockout) in same study","pmids":["34572144"],"is_preprint":false},{"year":2021,"finding":"Ligand-specific reduction of β-arrestin-2 recruitment at GCGR (via partial agonism of OXM-derived co-agonists) slows GLP-1R internalization and prolongs glucose-lowering action in vivo, while retaining GCGR-mediated weight loss via increased energy expenditure. This establishes that GCGR co-agonism contributes weight loss through energy expenditure mechanisms distinct from food intake suppression.","method":"Cell-based β-arrestin-2 recruitment assays, receptor internalization assays, molecular dynamics simulations, in vivo glucose homeostasis and weight loss studies in mice","journal":"Molecular Metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — cellular signaling assays plus in vivo validation; mechanism of β-arrestin-2-dependent GLP-1R internalization established","pmids":["33933675"],"is_preprint":false},{"year":2021,"finding":"19F-NMR studies of detergent-reconstituted GCGR in micelles and nanodiscs reveal that the negative allosteric modulator NNC0640 binding to the GCGR transmembrane domain confers the long-time stability required for NMR experiments, and produces distinct allosteric effects on receptor dynamics detectable via 19F probes on indigenous cysteines.","method":"19F-NMR spectroscopy, paramagnetic relaxation enhancement, detergent/nanodisc reconstitution, post-translational chemical labeling","journal":"The FEBS Journal","confidence":"Medium","confidence_rationale":"Tier 1 — solution NMR with site-specific labeling; novel conformational dynamics data, single study","pmids":["33369025"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structures of GLP-1R and GCGR each in complex with Gs protein and three different dual GLP-1R/GCGR agonists (peptide 15, cotadutide/MEDI0382, SAR425899) reveal that distinct side chain orientations within the first three peptide residues determine receptor selectivity. The middle region of dual agonists engages ECL1, ECL2, and top of TM1, causing specific conformational changes; dual agonists reshape ECL1 conformation of GLP-1R relative to GCGR. Lipid moiety of MEDI0382 interacts with TM1-TM2 cleft of GCGR, explaining its increased potency at GCGR.","method":"Cryo-electron microscopy (high-resolution), structural analysis of multiple agonist-receptor-Gs complexes, pharmacological validation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — multiple cryo-EM structures with pharmacological validation defining molecular basis of dual agonism","pmids":["37549266"],"is_preprint":false},{"year":2023,"finding":"Super-resolution dSTORM imaging of HepG2 cells reveals that GCGR forms nanoscale clusters on the plasma membrane. High glucose promotes increased GCGR expression and formation of larger, more numerous clusters. Under high glucose, glucagon stimulation fails to suppress GCGR cluster levels or increase downstream cAMP-PKA signaling, demonstrating that high glucose induces glucagon resistance at the receptor level. Hepatoma cells display stronger glucagon resistance than normal hepatic cells under high glucose.","method":"Direct stochastic optical reconstruction microscopy (dSTORM), cAMP-PKA signaling assays, GCGR expression quantification in HepG2 vs. primary hepatic cells","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 — direct super-resolution localization imaging with functional signaling readout; novel mechanistic link between GCGR membrane clustering and glucagon resistance","pmids":["36824278"],"is_preprint":false},{"year":2023,"finding":"GLP-1 selectively binds the extracellular surface of GLP-1R transmembrane domain (TMD) even in the absence of the ECD, as shown by paramagnetic NMR. Cross-reactivity of GLP-1R with glucagon and GCGR with GLP-1 was demonstrated, providing molecular evidence of receptor cross-reactivity in solution relevant to dual agonist pharmacology.","method":"Paramagnetic NMR relaxation enhancement, dual 19F/nitroxide spin labeling of receptor and peptide ligands, solution-state measurements of GLP-1R-TMD and GCGR","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 1 — NMR with site-specific labeling providing direct evidence of binding site and cross-reactivity; single study","pmids":["37332600"],"is_preprint":false},{"year":2023,"finding":"In Japanese flounder hepatocytes, glucagon promotes gluconeogenesis through a defined GCGR/PKA/CREB/PGC-1α pathway: GCGR activation increases Gs/adenylyl cyclase activity, elevating cAMP, which activates PKA to phosphorylate CREB, which induces PGC-1α expression, leading to upregulation of gluconeogenic genes pck1 and g6pc and glucose production. Each step was validated by specific inhibitors and GCGR overexpression.","method":"Primary hepatocyte culture, pharmacological inhibitors of GCGR/PKA/CREB/PGC-1α, gcgr gene overexpression, mRNA/protein quantification, glucose production assay","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 — systematic pharmacological dissection with overexpression rescue in fish hepatocytes; consistent with mammalian GCGR pathway","pmids":["37048171"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM structures of human GLP-1R, GCGR, and GIPR in complex with Gs proteins in the absence of cognate ligands reveal that Gs protein alone directly opens the intracellular binding cavity and rewires the extracellular orthosteric pocket. In ligand-free GCGR, a segment of ECL2 partially occupies the peptide-binding site. These ligand-free structures demonstrate that Gs protein can mobilize the intracellular transmembrane domain and rearrange the extracellular region to a transitional conformation facilitating peptide N-terminus entry.","method":"Cryo-electron microscopy (high-resolution), structural comparison of ligand-free vs. ligand-bound receptor-Gs complexes","journal":"Cell Discovery","confidence":"High","confidence_rationale":"Tier 1 — high-resolution cryo-EM structures with detailed structural analysis defining G protein-driven receptor activation mechanism","pmids":["38346960"],"is_preprint":false},{"year":2024,"finding":"ALKBH5, an RNA m6A demethylase, is phosphorylated by protein kinase A (PKA), causing its translocation from the nucleus to the cytosol. Hepatocyte-specific Alkbh5 deletion inhibits GCGR signaling pathways and reduces glucose and lipid levels. ALKBH5 regulates glucose homeostasis through the GCGR pathway and lipid homeostasis through mTORC1, establishing ALKBH5 as a regulator upstream of GCGR-mediated metabolic signaling.","method":"Hepatocyte-specific conditional knockout, PKA phosphorylation assays, metabolic phenotyping (glucose/lipid measurements), pathway analysis","journal":"Science","confidence":"Medium","confidence_rationale":"Tier 2 — conditional hepatic KO with metabolic phenotyping establishing ALKBH5-GCGR regulatory relationship; single study","pmids":["40014709"],"is_preprint":false},{"year":2024,"finding":"CD9 (tetraspanin) mediates hepatic effects of GCGR agonism. GCGR activation upregulates hepatic CD9 expression. CD9 deficiency exacerbates diet-induced hepatic steatosis via complement factor D (CFD)-regulated fatty acid metabolism; CD9 modulates hepatic fatty acid synthesis and oxidation genes through regulating CFD expression via ubiquitination-proteasomal degradation of FLI1. Blockade of CD9 abolishes cotadutide (GCGR/GLP-1R agonist)-induced remission of hepatic steatosis.","method":"Hepatic CD9 knockdown/knockout, GCGR agonist treatment (cotadutide), ubiquitination assays, adipose thermogenesis measurement, hepatic gene expression","journal":"Advanced Science","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway from GCGR to CD9/CFD/FLI1 established with KO and rescue experiments; single study","pmids":["38837628"],"is_preprint":false},{"year":2024,"finding":"Downregulation of GCGR and GLP1R in stenotic ileum of Crohn's disease patients and fibrotic mouse colon leads to accumulation of metabolic lactate, resulting in histone H3K9 lactylation in epithelial cells and epithelial-to-mesenchymal transition (EMT)-driven intestinal fibrosis. Dual GCGR/GLP1R activation by peptide 1907B reduces H3K9 lactylation and ameliorates intestinal fibrosis in vivo, establishing GCGR's role in regulating epithelial energy metabolism and EMT.","method":"Patient tissue analysis, chronic colitis mouse model, histone lactylation assays, EMT marker analysis, dual agonist treatment in vivo","journal":"Acta Pharmaceutica Sinica B","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway linking GCGR signaling to lactate/histone lactylation/EMT established with in vivo validation; single study","pmids":["40041889"],"is_preprint":false},{"year":2024,"finding":"Hepatic GCGR is the critical mediator of superior weight loss and lipid clearance achieved by the dual GCGR/GLP1R agonist BI 456908 compared to selective GLP1R agonism. Hepatic GCGR engagement facilitates plasma and liver lipid clearance, demonstrating a direct hepatic GCGR contribution to the metabolic efficacy of dual agonism.","method":"Comparison of dual agonist (BI 456908) vs. selective GLP1R agonist (semaglutide) in vivo; liver-specific mechanistic assessment; body weight and lipid profiling","journal":"bioRxiv (preprint)","confidence":"Low","confidence_rationale":"Tier 2-3 — preprint; pharmacological dissection without genetic confirmation of hepatic GCGR specificity","pmids":["bio_10.1101_2024.09.09.611134"],"is_preprint":true},{"year":2025,"finding":"RACK1 (Receptor for Activated C Kinase 1) functions as a dual-compartment scaffold for the hepatic glucagon-PKA-CREB signaling axis. RACK1 directly binds GCGR, PKA regulatory (RIIα) and catalytic (PKAcα) subunits, and CREB, assembling GCGR-PKA complexes at the plasma membrane and PKAcα-CREB complexes in the nucleus. Loss of hepatic RACK1 impairs PKAcα translocation, CREB phosphorylation, and gluconeogenic gene expression, causing fasting hypoglycemia. These defects are rescued by constitutively active PKAcα.","method":"Acute hepatic RACK1 deletion (mouse liver), co-immunoprecipitation, GST pulldown, proximity ligation assay, confocal microscopy, cell fractionation, glucose/pyruvate tolerance tests, hepatocyte glucose production assay, PKAcα W196R rescue experiment","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (Co-IP, GST pulldown, PLA, imaging, fractionation) with genetic rescue; preprint status limits confidence","pmids":["bio_10.1101_2025.06.18.660434"],"is_preprint":true},{"year":2025,"finding":"GCGR agonism in obese mice recruits GABAergic signaling in the medial basal hypothalamus to promote UCP1-dependent thermogenesis in adipose tissue, increase caloric expenditure, and drive negative energy balance. This establishes a liver→brain→fat axis for GCGR-mediated weight loss, with weight loss occurring primarily through augmented metabolic rate rather than food intake reduction.","method":"Chronic GCGR agonist treatment in obese mice, metabolic cage studies at room temperature and thermoneutrality, hypothalamic circuit manipulation (GABAergic signaling), UCP1 protein measurement in adipose tissue, body composition analysis","journal":"Molecular Metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — defined neural circuit mechanism with specific thermogenic readout; single study, not yet peer-reviewed in corpus but published","pmids":["41654017"],"is_preprint":false},{"year":2025,"finding":"Ligand-induced β-arrestin recruitment to GCGR proceeds in a phosphorylation-independent manner, in contrast to GLP-1R and GIPR where phosphorylation of C-terminal tail residues is a critical determinant driving GPCR-β-arrestin complex formation. Mutagenesis of identified C-tail phosphorylation sites confirms unique receptor-specific effects on β-arrestin recruitment and cAMP production.","method":"Proteomic identification of C-tail phosphorylation sites (mass spectrometry), site-directed mutagenesis, β-arrestin recruitment assay, cAMP assay","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 1-2 — proteomic identification plus mutagenesis with functional assays; preprint status limits confidence","pmids":["bio_10.1101_2025.03.10.642457"],"is_preprint":true},{"year":2024,"finding":"Interruption of glucagon signaling (via GCGR antagonism or Gcgr knockout) augments delta cell and beta cell proliferation in mouse, zebrafish, and transplanted human islets. This proliferative response requires the cationic amino acid transporter SLC7A2 and mTORC1 activation — established by rapamycin sensitivity and SLC7A2-deficient models — linking GCGR-mediated amino acid sensing to islet non-alpha cell growth.","method":"Multiple models (zebrafish gcgr deficiency, rodent GCGR antagonism/KO, transplanted human islets), rapamycin inhibition, SLC7A2 global knockout, delta/beta cell proliferation quantification","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis established across six models with genetic and pharmacological confirmation of SLC7A2/mTORC1 requirement; preprint","pmids":["bio_10.1101_2024.08.06.606926"],"is_preprint":true},{"year":2025,"finding":"Avian GCGR is expressed at high levels in adipocytes (unlike mammalian GCGR which is minimally expressed in adipose). Avian GCGR or constitutively active human GCGR variant (GCGRH339R) expressed in white adipose tissue of obese male mice effectively promotes fat mobilization and sustained body weight loss, with decreased food intake partially contributing to weight reduction. This identifies adipose GCGR as a mechanism for continuous fat utilization.","method":"Cross-species single-nucleus RNA-sequencing, viral expression of avian GCGR and human GCGRH339R in mouse white adipose tissue, body composition and weight tracking, food intake measurement","journal":"Nature Communications","confidence":"Medium","confidence_rationale":"Tier 2 — snRNA-seq discovery with functional viral expression rescue in mouse adipose; novel adipose GCGR mechanism","pmids":["41315395"],"is_preprint":false},{"year":2025,"finding":"Globally eliminating GCGR signaling (Gcgr KO) decreases median lifespan by 35% in lean mice and 54% in obese mice. Glucagon receptor signaling is indispensable for the metabolic benefits of caloric restriction: while CR reduces liver fat, serum triglycerides and cholesterol in wild-type mice, these benefits are absent in Gcgr KO mice. Liver-specific Gcgr deletion decreases hepatic AMPK activation in aging mice regardless of diet, and abolishes CR-mediated suppression of mTOR activity.","method":"Global and liver-specific Gcgr knockout mice, dietary manipulation (caloric restriction), metabolic phenotyping (liver fat, lipids), AMPK and mTOR activity measurements","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis (global and liver-specific KO) with defined nutrient-sensing pathway readouts; preprint","pmids":["bio_10.1101_2025.05.13.653849"],"is_preprint":true}],"current_model":"GCGR is a class B GPCR expressed predominantly in liver, kidney, pancreatic islets, and other tissues that binds glucagon via a two-site mechanism (C-terminus to ECD, N-terminus to TMD binding pocket), requires its ECD as an active signaling participant, couples primarily to Gs (and secondarily Gi1) through intracellular loop contacts, activates the PKA/CREB/PGC-1α axis to drive hepatic gluconeogenesis (scaffolded by RACK1), promotes glycogenolysis, fatty acid oxidation, and amino acid catabolism in liver, stimulates cAMP via AC5 in pancreatic β-cells to potentiate insulin secretion, recruits β-arrestin in a phosphorylation-independent manner distinct from related receptors, and engages hypothalamic GABAergic circuits to drive UCP1-dependent thermogenesis in adipose tissue; loss-of-function mutations cause glucagon cell hyperplasia/neoplasia via interrupted feedback, while allosteric small-molecule antagonists bind an extra-helical TM6-TM7 site to prevent G protein coupling."},"narrative":{"teleology":[{"year":1994,"claim":"Molecular cloning of human GCGR from liver cDNA established it as a seven-transmembrane receptor that binds glucagon with high affinity and signals via cAMP, placing glucagon signaling within the GPCR superfamily and mapping the gene to chromosome 17q25.","evidence":"Heterologous expression in COS-7 cells with radioligand binding and cAMP assays; genomic Southern blot and in situ hybridization","pmids":["7507321","8144028"],"confidence":"High","gaps":["No structural information on receptor architecture","Downstream effectors beyond cAMP not identified","Tissue-specific signaling differences not addressed"]},{"year":1995,"claim":"Identification of the Gly40Ser missense variant linked to NIDDM demonstrated that single amino acid changes in GCGR can reduce glucagon-binding affinity ~3-fold, establishing the receptor as a diabetes-relevant locus.","evidence":"Site-directed mutagenesis with radioligand binding in transfected cells combined with genetic association","pmids":["7773293"],"confidence":"High","gaps":["Downstream signaling consequences of reduced affinity not measured","Causal role vs. association not definitively resolved","No structural basis for affinity loss"]},{"year":2003,"claim":"Systematic mutagenesis and chimeric receptor studies defined the two-site binding model: the ECD captures the glucagon C-terminus while three distinct TMD epitopes recognize the glucagon N-terminus, providing the first molecular framework for ligand selectivity.","evidence":"Site-directed mutagenesis, chimeric receptors, radioligand binding and cAMP assays","pmids":["12724331"],"confidence":"High","gaps":["No atomic-resolution structure to confirm predicted contacts","Dynamics of binding transition not captured","Mechanism of signaling transduction from binding to G protein engagement undefined"]},{"year":2011,"claim":"Global Gcgr knockout mice revealed the full metabolic scope of GCGR signaling: loss abolished hepatic gluconeogenesis and amino acid catabolism while upregulating glycolysis and lipogenesis, establishing GCGR as a master regulator of hepatic fuel selection.","evidence":"Gcgr-/- mouse with tri-omic profiling (transcriptomics, proteomics, metabolomics)","pmids":["21631939"],"confidence":"High","gaps":["Cell-autonomous vs. systemic effects not dissected","Compensatory hormonal changes (hyperglucagonemia, elevated GLP-1) confound interpretation","Tissue-specific contributions not resolved"]},{"year":2013,"claim":"The first crystal structure of the GCGR TMD at 3.4 Å revealed a uniquely extended TM1 stalk that positions the ECD for glucagon capture, providing atomic-level understanding of the two-site binding mechanism and identifying the large orthosteric pocket.","evidence":"X-ray crystallography (3.4 Å) with extensive mutagenesis and hybrid modeling","pmids":["23863937"],"confidence":"High","gaps":["Structure captured only the TMD, not full-length receptor","No agonist-bound conformation","G protein coupling interface not visualized"]},{"year":2015,"claim":"Loss-of-function GCGR germline mutations were shown to cause glucagon cell adenomatosis, directly linking interrupted glucagon feedback through GCGR to α-cell hyperplasia and neoplasia in humans.","evidence":"Sequencing of GCGR exons in GCA patients with clinicopathological correlation and control genotyping","pmids":["25695890"],"confidence":"Medium","gaps":["Precise mechanism by which absent signaling drives proliferation not defined","Small patient cohort","No functional reconstitution of identified mutations"]},{"year":2016,"claim":"The crystal structure of GCGR bound to MK-0893 revealed an unprecedented extra-helical allosteric antagonist site between TM6 and TM7 that blocks the TM6 outward movement required for G protein coupling, opening a new pharmacological modality for GCGR inhibition.","evidence":"X-ray crystallography (2.5 Å) of GCGR–MK-0893 complex with mutagenesis and cAMP assays","pmids":["27111510"],"confidence":"High","gaps":["Whether other class B GPCRs share this site not established","Effect on β-arrestin recruitment not tested","In vivo relevance of allosteric inhibition mechanism not confirmed structurally"]},{"year":2016,"claim":"Covalent tethering experiments demonstrated that the GCGR ECD is an obligate active participant in signal transduction rather than a passive affinity trap, distinguishing GCGR from other class B GPCRs where the ECD requirement can be bypassed.","evidence":"Covalent peptide–TMD linkage with chimeric receptors and cAMP assays","pmids":["27226600"],"confidence":"High","gaps":["Structural basis for ECD's active signaling role not determined","Which ECD residues mediate signaling vs. binding not dissected"]},{"year":2017,"claim":"The full-length inactive GCGR structure revealed the stalk adopts a β-strand (not α-helical) conformation forming a β-sheet with ECL1, resolving the structural basis for ECD–TMD communication and identifying the stalk/ECL1 as a conformational switch controlling ligand access.","evidence":"X-ray crystallography (3.0 Å full-length), HDX, disulfide crosslinking, molecular dynamics","pmids":["28514451"],"confidence":"High","gaps":["Active-state full-length structure not yet available at this point","Mechanism by which stalk rearrangement transmits signal to TMD not fully defined"]},{"year":2018,"claim":"The crystal structure of GCGR bound to glucagon analogue NNC1702 captured the peptide-engaged state, showing that stalk and ECL1 undergo major secondary-structure rearrangements during activation and establishing a 'dual-binding-site trigger model' for class B GPCR activation.","evidence":"X-ray crystallography (3.0 Å, full-length GCGR–peptide complex)","pmids":["29300013"],"confidence":"High","gaps":["G protein coupling geometry not captured in same structure","Dynamics of transition from inactive to active not resolved"]},{"year":2020,"claim":"Cryo-EM structures of GCGR–glucagon complexes with both Gs and Gi1 revealed the structural basis for G protein selectivity: Gs forms a larger interface with GCGR intracellular loops, explaining preferential Gs coupling while showing Gi1 engagement uses the same open cavity.","evidence":"Cryo-EM of two GCGR–G protein complexes with mutagenesis validation","pmids":["32193322"],"confidence":"High","gaps":["Kinetic basis for Gs preference over Gi not addressed","βγ subunit contributions to selectivity not dissected","Gq coupling not tested"]},{"year":2021,"claim":"β-cell GCGR was shown to potentiate glucose-stimulated insulin secretion at physiological glucose via AC5-dependent cAMP elevation, with β-cell-specific GCGR knockout mice developing exacerbated glucose intolerance on high-fat diet, establishing a direct paracrine α→β cell glucagon circuit.","evidence":"Single β-cell and islet cAMP imaging, AC family inhibitors, β-cell-specific GCGR knockout mice","pmids":["34572144"],"confidence":"High","gaps":["Relative contribution of GCGR vs. GLP-1R in β-cell cAMP generation under physiological conditions not quantified","Whether AC5 specificity is universal across species not confirmed"]},{"year":2023,"claim":"Multiple cryo-EM structures of GCGR with dual GLP-1R/GCGR agonists defined how the first three peptide residues determine receptor selectivity and how lipid moieties on agonists engage the TM1–TM2 cleft, providing a structural template for rational design of dual agonist therapeutics.","evidence":"Cryo-EM of three dual agonist–GCGR–Gs complexes with pharmacological validation","pmids":["37549266"],"confidence":"High","gaps":["β-arrestin-biased signaling by dual agonists not structurally characterized","In vivo tissue-specific signaling outcomes of differential receptor engagement not resolved"]},{"year":2024,"claim":"Ligand-free cryo-EM structures showed that Gs protein alone can open the GCGR intracellular cavity and partially remodel the extracellular peptide-binding site, with ECL2 occupying the orthosteric pocket in the absence of peptide — demonstrating that G protein pre-coupling creates a transitional state facilitating agonist entry.","evidence":"Cryo-EM of ligand-free GCGR–Gs complex with structural comparison to ligand-bound states","pmids":["38346960"],"confidence":"High","gaps":["Physiological relevance of ligand-free G protein pre-coupling not established in cells","Whether this mechanism operates for Gi coupling not tested"]},{"year":2024,"claim":"GCGR blockade was shown to drive δ-cell and β-cell proliferation through SLC7A2-dependent amino acid transport and mTORC1 activation, linking GCGR-regulated amino acid homeostasis to islet cell mass expansion across zebrafish, mouse, and human islet models.","evidence":"Multi-species models (zebrafish, rodent KO/antagonism, transplanted human islets), rapamycin inhibition, SLC7A2 knockout (preprint)","pmids":["bio_10.1101_2024.08.06.606926"],"confidence":"Medium","gaps":["Not peer-reviewed","Mechanism by which elevated amino acids activate mTORC1 specifically in δ/β cells not defined","Long-term consequences of proliferation not assessed"]},{"year":2025,"claim":"RACK1 was identified as a dual-compartment scaffold that physically links GCGR to PKA subunits at the plasma membrane and PKAcα to CREB in the nucleus, with hepatic RACK1 deletion causing fasting hypoglycemia reversible by constitutively active PKAcα — establishing the first scaffolding mechanism for spatial organization of the glucagon–PKA–CREB cascade.","evidence":"Hepatic RACK1 deletion, co-IP, GST pulldown, proximity ligation assay, cell fractionation, PKAcα rescue (preprint)","pmids":["bio_10.1101_2025.06.18.660434"],"confidence":"Medium","gaps":["Not peer-reviewed","Whether RACK1 scaffolding is GCGR-specific or shared with other Gs-coupled receptors not tested","Structural basis for RACK1–GCGR interaction not resolved"]},{"year":2025,"claim":"GCGR agonism was shown to engage hypothalamic GABAergic circuits that drive UCP1-dependent adipose thermogenesis, establishing a liver→brain→fat axis as the primary mechanism for GCGR-mediated energy expenditure and weight loss rather than appetite suppression.","evidence":"Chronic GCGR agonism in obese mice with metabolic cages, hypothalamic GABAergic manipulation, UCP1 quantification","pmids":["41654017"],"confidence":"Medium","gaps":["Afferent signal from liver to hypothalamus not identified","Whether this axis operates in humans not established","Relative contribution of direct hepatic vs. CNS-mediated effects not quantified"]},{"year":2025,"claim":"β-arrestin recruitment to GCGR was shown to be phosphorylation-independent, contrasting sharply with GLP-1R and GIPR where C-tail phosphorylation is required — revealing receptor-specific desensitization mechanisms among closely related class B GPCRs.","evidence":"Mass spectrometry phosphosite identification, site-directed mutagenesis, β-arrestin recruitment and cAMP assays (preprint)","pmids":["bio_10.1101_2025.03.10.642457"],"confidence":"Medium","gaps":["Not peer-reviewed","Structural basis for phosphorylation-independent β-arrestin engagement not determined","In vivo consequences for receptor desensitization and trafficking not established"]},{"year":null,"claim":"Major open questions include the identity of the afferent signal linking hepatic GCGR activation to hypothalamic thermogenic circuits, the structural basis for phosphorylation-independent β-arrestin recruitment, whether G protein pre-coupling operates physiologically in native hepatocytes, and the long-term safety implications of GCGR-driven islet cell proliferation for dual-agonist therapeutics.","evidence":"","pmids":[],"confidence":"Low","gaps":["Liver-to-brain signal mediating thermogenesis unidentified","No structure of GCGR–β-arrestin complex","Physiological relevance of ligand-free G protein pre-coupling untested in primary cells"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,3,12,17]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[18,24]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,22,30]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,17,18,24]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[4,13,14,27]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,8]}],"complexes":[],"partners":["GNA5","GNAI1","ARRB2","AC5","RACK1","CD9"],"other_free_text":[]},"mechanistic_narrative":"GCGR is a class B G protein-coupled receptor that serves as the principal mediator of glucagon's metabolic actions, coupling ligand binding to Gs-dependent cAMP elevation to drive hepatic gluconeogenesis, glycogenolysis, amino acid catabolism, and fatty acid oxidation [PMID:7507321, PMID:21631939, PMID:23185367]. Glucagon engages GCGR through a two-site mechanism in which the peptide C-terminus binds the extracellular domain (ECD) and the N-terminus inserts into the transmembrane domain (TMD) pocket, with the ECD playing an obligate active role in receptor activation beyond simple affinity capture; stalk and ECL1 conformational rearrangements trigger TMD opening for G protein engagement [PMID:12724331, PMID:27226600, PMID:29300013]. GCGR couples primarily to Gs and secondarily to Gi1 through a larger Gs interaction interface, recruits β-arrestin in a phosphorylation-independent manner distinct from related incretin receptors, and is inhibited by allosteric small-molecule antagonists that bind an extra-helical TM6–TM7 site to prevent TM6 outward movement [PMID:32193322, PMID:27111510, PMID:bio_10.1101_2025.03.10.642457]. Loss-of-function GCGR mutations cause glucagon cell adenomatosis characterized by multifocal α-cell hyperplasia and neoplasia due to interrupted glucagon feedback [PMID:25695890]."},"prefetch_data":{"uniprot":{"accession":"P47871","full_name":"Glucagon receptor","aliases":[],"length_aa":477,"mass_kda":54.0,"function":"G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase (PubMed:32193322, PubMed:38346960). Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P47871/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GCGR","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GCGR","total_profiled":1310},"omim":[{"mim_id":"619290","title":"MAHVASH DISEASE; MVAH","url":"https://www.omim.org/entry/619290"},{"mim_id":"613303","title":"AlkB HOMOLOG 5, RNA DEMETHYLASE; ALKBH5","url":"https://www.omim.org/entry/613303"},{"mim_id":"603659","title":"GLUCAGON-LIKE PEPTIDE 2 RECEPTOR; GLP2R","url":"https://www.omim.org/entry/603659"},{"mim_id":"138033","title":"GLUCAGON RECEPTOR; GCGR","url":"https://www.omim.org/entry/138033"},{"mim_id":"138032","title":"GLUCAGON-LIKE PEPTIDE 1 RECEPTOR; GLP1R","url":"https://www.omim.org/entry/138032"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Golgi apparatus","reliability":"Uncertain"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"kidney","ntpm":49.3},{"tissue":"liver","ntpm":167.2}],"url":"https://www.proteinatlas.org/search/GCGR"},"hgnc":{"alias_symbol":["GGR"],"prev_symbol":[]},"alphafold":{"accession":"P47871","domains":[{"cath_id":"4.10.1240.10","chopping":"25-100","consensus_level":"high","plddt":91.5375,"start":25,"end":100},{"cath_id":"1.20.1070.10","chopping":"138-366_382-406","consensus_level":"high","plddt":87.6816,"start":138,"end":406}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P47871","model_url":"https://alphafold.ebi.ac.uk/files/AF-P47871-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P47871-F1-predicted_aligned_error_v6.png","plddt_mean":81.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GCGR","jax_strain_url":"https://www.jax.org/strain/search?query=GCGR"},"sequence":{"accession":"P47871","fasta_url":"https://rest.uniprot.org/uniprotkb/P47871.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P47871/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P47871"}},"corpus_meta":[{"pmid":"36356832","id":"PMC_36356832","title":"BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.","date":"2022","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36356832","citation_count":101,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21631939","id":"PMC_21631939","title":"Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes.","date":"2011","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/21631939","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30765435","id":"PMC_30765435","title":"Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy.","date":"2019","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/30765435","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40014709","id":"PMC_40014709","title":"Liver ALKBH5 regulates glucose and lipid homeostasis independently through GCGR and mTORC1 signaling.","date":"2025","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/40014709","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34572144","id":"PMC_34572144","title":"Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34572144","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35646543","id":"PMC_35646543","title":"Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis.","date":"2021","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/35646543","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27211075","id":"PMC_27211075","title":"DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops.","date":"2016","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/27211075","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37549266","id":"PMC_37549266","title":"Structural analysis of the dual agonism at GLP-1R and GCGR.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37549266","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38755312","id":"PMC_38755312","title":"Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency.","date":"2024","source":"Nature chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38755312","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29937214","id":"PMC_29937214","title":"GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr-/- mice and is dispensable for the metabolic benefits ensuing after vertical sleeve gastrectomy.","date":"2018","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29937214","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34411824","id":"PMC_34411824","title":"Gestational cadmium exposure impairs placental angiogenesis via activating GC/GR signaling.","date":"2021","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/34411824","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39735270","id":"PMC_39735270","title":"GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.","date":"2024","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/39735270","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38346960","id":"PMC_38346960","title":"Molecular features of the ligand-free GLP-1R, GCGR and GIPR in complex with Gs proteins.","date":"2024","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38346960","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30294546","id":"PMC_30294546","title":"The first pediatric case of glucagon receptor defect due to biallelic mutations in GCGR is identified by newborn screening of elevated arginine.","date":"2018","source":"Molecular genetics and metabolism reports","url":"https://pubmed.ncbi.nlm.nih.gov/30294546","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40041889","id":"PMC_40041889","title":"Dual activation of GCGR/GLP1R signaling ameliorates intestinal fibrosis via metabolic regulation of histone H3K9 lactylation in epithelial cells.","date":"2024","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/40041889","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33933675","id":"PMC_33933675","title":"Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.","date":"2021","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33933675","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38065435","id":"PMC_38065435","title":"Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.","date":"2023","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38065435","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33369025","id":"PMC_33369025","title":"Design and preparation of the class B G protein-coupled receptors GLP-1R and GCGR for 19 F-NMR studies in solution.","date":"2021","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/33369025","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28132162","id":"PMC_28132162","title":"Population pharmacokinetics and pharmacodynamics of IONIS-GCGRRx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model.","date":"2017","source":"Journal of pharmacokinetics and pharmacodynamics","url":"https://pubmed.ncbi.nlm.nih.gov/28132162","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37800952","id":"PMC_37800952","title":"Alpinia katsumadai Hayata Volatile Oil Is Effective in Treating 5-Fluorouracil-Induced Mucositis by Regulating Gut Microbiota and Modulating the GC/GR Pathway and the mPGES-1/PGE2/EP4 Pathways.","date":"2023","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37800952","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38560764","id":"PMC_38560764","title":"The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.","date":"2024","source":"Diabetes, obesity & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38560764","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40479843","id":"PMC_40479843","title":"Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.","date":"2025","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/40479843","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40399267","id":"PMC_40399267","title":"GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic β-cell function in obese male mice.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40399267","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33920024","id":"PMC_33920024","title":"Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33920024","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37048171","id":"PMC_37048171","title":"Glucagon Promotes Gluconeogenesis through the GCGR/PKA/CREB/PGC-1α Pathway in Hepatocytes of the Japanese Flounder Paralichthys olivaceus.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37048171","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30312651","id":"PMC_30312651","title":"Glucagon-like peptides-1 from phylogenetically ancient fish show potent anti-diabetic activities by acting as dual GLP1R and GCGR agonists.","date":"2018","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30312651","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38837628","id":"PMC_38837628","title":"CD9 Counteracts Liver Steatosis and Mediates GCGR Agonist Hepatic Effects.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38837628","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32073000","id":"PMC_32073000","title":"Graph theory-based reaction pathway searches and DFT calculations for the mechanism studies of free radical-initiated peptide sequencing mass spectrometry (FRIPS MS): a model gas-phase reaction of GGR tri-peptide.","date":"2020","source":"Physical chemistry chemical physics : PCCP","url":"https://pubmed.ncbi.nlm.nih.gov/32073000","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36824278","id":"PMC_36824278","title":"High glucose-induced glucagon resistance and membrane distribution of GCGR revealed by super-resolution imaging.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/36824278","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40466507","id":"PMC_40466507","title":"Chlorogenic acid and ferulic acid in SMYAD alleviate diabetic cardiomyopathy by inhibiting cardiac lipotoxicity via GCGR/PPARα and GCGR/AMPK pathways.","date":"2025","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40466507","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32785645","id":"PMC_32785645","title":"The V369M Gcgr knock-in mice are a precision medicine model of mild Mahvash disease.","date":"2020","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/32785645","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40958513","id":"PMC_40958513","title":"Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects.","date":"2025","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40958513","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37332600","id":"PMC_37332600","title":"Selective polypeptide ligand binding to the extracellular surface of the transmembrane domains of the class B GPCRs GLP-1R and GCGR.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37332600","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40499218","id":"PMC_40499218","title":"Tanshinone IIA improved psychological stress-induced embryo implantation disorders by inhibiting GC/GR signaling and promoting angiogenesis.","date":"2025","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40499218","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41260780","id":"PMC_41260780","title":"DeepGCGR: an interpretable two-layer deep learning model for the discovery of GCGR-activating compounds.","date":"2025","source":"Chinese journal of natural medicines","url":"https://pubmed.ncbi.nlm.nih.gov/41260780","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34002801","id":"PMC_34002801","title":"Deleterious mutation V369M in the mouse GCGR gene causes abnormal plasma amino acid levels indicative of a possible liver-α-cell axis.","date":"2021","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/34002801","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40619099","id":"PMC_40619099","title":"Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.","date":"2025","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/40619099","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41246119","id":"PMC_41246119","title":"Dual GIP/GLP1-RA, GCGR/GLP-1 RA and GLP1-RA for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease with Type 2 Diabetes: A Systematic Review and Meta-analysis.","date":"2025","source":"TouchREVIEWS in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/41246119","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37969012","id":"PMC_37969012","title":"Evolution of GCGR family ligand-receptor extensive cross-interaction systems suggests a therapeutic direction for hyperglycemia in mammals.","date":"2023","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/37969012","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39125959","id":"PMC_39125959","title":"The Inferential Binding Sites of GCGR for Small Molecules Using Protein Dynamic Conformations and Crystal Structures.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39125959","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41280890","id":"PMC_41280890","title":"A novel GCGR/GLP-1R dual-agonist TB001 ameliorates kidney fibrosis via inhibiting PERK-mediated endoplasmic reticulum stress pathway.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41280890","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40832525","id":"PMC_40832525","title":"Novel Peptides as GIPR/GLP-1R/GCGR Triagonists for Treating Type 2 Diabetes Mellitus.","date":"2025","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/40832525","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41030857","id":"PMC_41030857","title":"Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.","date":"2025","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/41030857","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41315395","id":"PMC_41315395","title":"Avian GCGR-mediated continuous fat utilization offers perspectives for obesity treatment.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41315395","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41869515","id":"PMC_41869515","title":"Design and biological evaluation of triagonist GLP-1R/GCGR/GIPR peptides as potential therapeutic agents for diabetes and obesity.","date":"2026","source":"RSC medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/41869515","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35381520","id":"PMC_35381520","title":"Generation of an induced pluripotent stem cell (iPSC) line from a diabetic patient with glucagon receptor (GCGR) p.W83X mutation.","date":"2022","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/35381520","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41654017","id":"PMC_41654017","title":"GCGR agonism requires GABAergic signaling in the medial basal hypothalamus to promote weight loss in obese mice.","date":"2026","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/41654017","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.06.06.658268","title":"Blind De Novo Design of Dual Cyclic Peptide Agonists Targeting GCGR and GLP1R","date":"2025-06-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.06.658268","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.06.18.660434","title":"A Dual-Compartment Scaffolding Role for RACK1 in Hepatic Glucagon Signaling and Gluconeogenesis","date":"2025-06-24","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.18.660434","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.05.13.653849","title":"Glucagon receptor signaling is indispensable for the healthspan effects of caloric restriction in aging male mice","date":"2025-05-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.13.653849","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.08.09.669458","title":"Glycemia Shift Pancreatic Islets Rhythmicity via δ-α Cell <i>in vivo</i>, Impairment in Diabetes","date":"2025-08-12","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.09.669458","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.03.06.641926","title":"Identification of drug candidates against glioblastoma with machine learning and high-throughput screening of heterogeneous cellular models","date":"2025-03-07","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.06.641926","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.03.10.642457","title":"Differential role of phosphorylation in glucagon family receptor signaling revealed by mass spectrometry","date":"2025-03-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.10.642457","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.09.09.611134","title":"Hepatic GCGR is required for the superior weight loss effects of a structurally related analogue of the dual GCGR/GLP1R agonist survodutide","date":"2024-09-13","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.09.611134","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.03.23.644666","title":"<i>De novo</i> design of miniprotein agonists and antagonists targeting G protein-coupled receptors","date":"2025-03-23","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.23.644666","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.08.06.606926","title":"Interruption of glucagon signaling augments islet non-alpha cell proliferation in SLC7A2- and mTOR-dependent manners","date":"2024-08-07","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.06.606926","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.04.01.646483","title":"Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues","date":"2025-04-07","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.01.646483","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.10.21.619544","title":"Pancreatic islet α cells regulate microtubule stability in neighboring β cells to tune insulin secretion and induce functional heterogeneity in individual mouse and human islets","date":"2024-10-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.21.619544","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.11.26.625442","title":"Drug combinations targeting FAK and MEK overcomes tumour heterogeneity in glioblastoma","date":"2024-12-01","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.26.625442","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12626323","id":"PMC_12626323","title":"Glucagon and regulation of glucose metabolism.","date":"2003","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12626323","citation_count":635,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23863937","id":"PMC_23863937","title":"Structure of the human glucagon class B G-protein-coupled receptor.","date":"2013","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23863937","citation_count":302,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21988832","id":"PMC_21988832","title":"Toward an understanding of the protein interaction network of the human liver.","date":"2011","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/21988832","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24359917","id":"PMC_24359917","title":"Insights into the structure of class B GPCRs.","date":"2013","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24359917","citation_count":182,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27111510","id":"PMC_27111510","title":"Extra-helical binding site of a glucagon receptor antagonist.","date":"2016","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/27111510","citation_count":178,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514451","id":"PMC_28514451","title":"Structure of the full-length glucagon class B G-protein-coupled receptor.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514451","citation_count":173,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7773293","id":"PMC_7773293","title":"A missense mutation in the glucagon receptor gene is associated with non-insulin-dependent diabetes mellitus.","date":"1995","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7773293","citation_count":166,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24749050","id":"PMC_24749050","title":"Action and therapeutic potential of oxyntomodulin.","date":"2013","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24749050","citation_count":137,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32193322","id":"PMC_32193322","title":"Structural basis of Gs and Gi recognition by the human glucagon receptor.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32193322","citation_count":130,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8144028","id":"PMC_8144028","title":"The human glucagon receptor encoding gene: structure, cDNA sequence and chromosomal localization.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8144028","citation_count":114,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29300013","id":"PMC_29300013","title":"Structure of the glucagon receptor in complex with a glucagon analogue.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29300013","citation_count":108,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26227798","id":"PMC_26227798","title":"Conformational states of the full-length glucagon receptor.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26227798","citation_count":97,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18240029","id":"PMC_18240029","title":"Reviews in molecular biology and biotechnology: transmembrane signaling by G protein-coupled receptors.","date":"2008","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/18240029","citation_count":92,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15188402","id":"PMC_15188402","title":"Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry.","date":"2004","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/15188402","citation_count":77,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31586073","id":"PMC_31586073","title":"The midbody interactome reveals unexpected roles for PP1 phosphatases in cytokinesis.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31586073","citation_count":74,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12724331","id":"PMC_12724331","title":"Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12724331","citation_count":68,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7507321","id":"PMC_7507321","title":"Cloning and expression of a human glucagon receptor.","date":"1994","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/7507321","citation_count":66,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25451942","id":"PMC_25451942","title":"Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25451942","citation_count":61,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27226600","id":"PMC_27226600","title":"Differential Requirement of the Extracellular Domain in Activation of Class B G Protein-coupled Receptors.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27226600","citation_count":60,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8563746","id":"PMC_8563746","title":"Glucagon receptor gene mutation in essential hypertension.","date":"1996","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8563746","citation_count":55,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32571939","id":"PMC_32571939","title":"A combined activation mechanism for the glucagon receptor.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32571939","citation_count":54,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25695890","id":"PMC_25695890","title":"Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations.","date":"2015","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25695890","citation_count":52,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23185367","id":"PMC_23185367","title":"Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23185367","citation_count":48,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35784565","id":"PMC_35784565","title":"Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35784565","citation_count":39,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9105899","id":"PMC_9105899","title":"Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1).","date":"1997","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/9105899","citation_count":36,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":31873,"output_tokens":5486,"usd":0.088955},"stage2":{"model":"claude-opus-4-6","input_tokens":9144,"output_tokens":4148,"usd":0.22413},"total_usd":0.718125,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":43757,"output_tokens":9932,"usd":0.140125},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":13837,"output_tokens":4297,"usd":0.264915}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structures of GCGR in complex with heterotrimeric Gs protein and three dual GLP-1R/GCGR agonists (peptide 15, MEDI0382/cotadutide, SAR425899) revealed key residues for ligand recognition and dual agonism. Distinct side-chain orientations within the first three residues of the peptide determine receptor selectivity, ECL1 conformation of GLP-1R is reshaped by dual agonists relative to GCGR, and the lipid moiety of MEDI0382 interacts with the TM1-TM2 cleft to increase GCGR potency.\",\n      \"method\": \"Cryo-electron microscopy structure determination, supported by pharmacological data\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution cryo-EM structures with multiple ligands and functional pharmacological validation\",\n      \"pmids\": [\"37549266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structures of ligand-free GCGR in complex with Gs protein (without cognate glucagon) revealed that the Gs protein alone directly opens the intracellular binding cavity and rearranges the extracellular orthosteric pocket; specifically, a segment of GCGR ECL2 partially occupies the peptide-binding site in this ligand-free state, indicating a distinct activation mechanism from the ligand-bound state.\",\n      \"method\": \"Cryo-electron microscopy structure determination\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution cryo-EM structure of novel ligand-free receptor-G protein complex\",\n      \"pmids\": [\"38346960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Glucagon potentiates insulin secretion via β-cell GCGR at physiological but not high glucose concentrations; GCGR activation evokes cAMP elevation via adenylyl cyclase 5 (AC5) in β-cells, independently of high glucose-stimulated cAMP elevation through the same AC5; β-cell-specific GCGR knockout mice showed more severe glucose intolerance on high-fat diet.\",\n      \"method\": \"Pharmacological inhibition with GCGR/GLP-1R antagonists in single β-cells, α-β cell clusters, isolated islets; genetically encoded cAMP fluorescence indicator (RAB-ICUE); specific AC family inhibitors; β-cell-specific GCGR knockout mice\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including live-cell biosensor imaging, pharmacological dissection, and conditional knockout with defined phenotype\",\n      \"pmids\": [\"34572144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Complete ablation of hepatic glucagon receptor function (Gcgr-/- mice) causes significant down-regulation of gluconeogenesis, amino acid catabolism, and fatty acid oxidation, with up-regulation of glycolysis, fatty acid synthesis, and cholesterol biosynthesis in liver, manifested as decreased plasma glucose and increased plasma amino acids and cholesterol.\",\n      \"method\": \"Transcriptomic profiling (Affymetrix arrays), proteomic profiling (iTRAQ), and metabolite profiling (~200 analytes by MS) in Gcgr-/- vs wild-type mice\",\n      \"journal\": \"BMC genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — three orthogonal omics platforms with strong concordance (R=0.88) between transcript and protein data in a genetic knockout model\",\n      \"pmids\": [\"21631939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Ligand-specific reductions in β-arrestin-2 recruitment to GCGR were associated with slower receptor internalisation and prolonged glucose-lowering action in vivo; partial agonism (rather than biased agonism) at both G protein and β-arrestin-2 pathways was responsible for improved therapeutic efficacy of OXM-derived GLP-1R/GCGR co-agonists.\",\n      \"method\": \"Cell-based β-arrestin-2 recruitment assays, receptor internalisation assays, molecular dynamic simulations, in vivo glucose homeostasis and weight loss studies in mice\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple cellular assays with in vivo validation, single lab\",\n      \"pmids\": [\"33933675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In Gcgr-/-:Glp2r-/- double knockout mice, loss of GLP-2R lowered circulating bile acid levels and attenuated small bowel growth normally seen in Gcgr-/- mice, but GLP-2R signaling was not required for improved glucose tolerance or elevated GLP-1 levels in Gcgr-/- mice; Gpbar1 (TGR5) did not mediate elevated proglucagon-derived peptide levels or major metabolic phenotypes in Gcgr-/- mice.\",\n      \"method\": \"Genetic epistasis using Gcgr-/-:Gpbar1-/-, Gcgr-/-:Glp2r-/- compound knockout mice; metabolic phenotyping including glucose tolerance tests, circulating hormone measurements, bile acid quantification\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple compound knockout lines and defined phenotypic readouts\",\n      \"pmids\": [\"29937214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"High glucose promoted GCGR expression and formation of larger nanoscale clusters on HepG2 cell membranes; glucagon stimulation under high glucose failed to suppress GCGR levels or increase downstream cAMP-PKA signaling as effectively as under low glucose, indicating high glucose-induced glucagon resistance at the receptor level.\",\n      \"method\": \"Direct stochastic optical reconstruction microscopy (dSTORM) super-resolution imaging of GCGR on cell membranes; cAMP-PKA downstream signaling assays\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct super-resolution localization with functional signaling readout, single lab\",\n      \"pmids\": [\"36824278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ALKBH5, an RNA m6A demethylase, is phosphorylated by protein kinase A causing its translocation to the cytosol; hepatocyte-specific deletion of Alkbh5 reduces glucose by inhibiting GCGR signaling pathway, placing ALKBH5 upstream of GCGR in a regulatory axis governing hepatic gluconeogenesis.\",\n      \"method\": \"Hepatocyte-specific Alkbh5 knockout mice; biochemical signaling assays; targeted knockdown in diabetic mouse models\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional knockout with defined metabolic phenotype, single lab study\",\n      \"pmids\": [\"40014709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NMR solution studies using 19F probes on GCGR and nitroxide spin labels on glucagon demonstrated that glucagon interacts with GCGR by selective binding to the extracellular surface of the transmembrane domain even in constructs lacking the extracellular domain (ECD), and cross-reactivity of GCGR with GLP-1 was also demonstrated.\",\n      \"method\": \"Paramagnetic NMR relaxation enhancement with dual 19F/nitroxide spin-label approach on purified receptor in nanodiscs\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — NMR in solution with functional dual-labeling; single lab, novel complementary insight to structural data\",\n      \"pmids\": [\"37332600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Addition of the negative allosteric modulator NNC0640 to the transmembrane domain of GLP-1R (but not GCGR) was critically important for obtaining long-time stability of these receptors in detergent micelles/nanodiscs for NMR studies, providing novel insights into allosteric effects from binding of NNC0640 to the transmembrane domain.\",\n      \"method\": \"19F-NMR spectroscopy of purified GCGR and GLP-1R with sequence-specific assignment of 19F-labels on indigenous cysteines; post-translational chemical introduction of fluorine probes\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biophysical characterization with functional comparison, single lab\",\n      \"pmids\": [\"33369025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Antagonistic GCGR-specific antibodies were identified that bind epitopes on both the extracellular domain (ECD) and extracellular loop regions (ECL) of GCGR; the ECD normally covers the small ECLs in the energetically most favorable 'closed conformation' of GCGR; scFv phage display was essential (over Fab display) due to avid interaction requirements for selecting ECL-binding clones on virus-like particles.\",\n      \"method\": \"Llama DNA immunization, scFv phage display, selections on VLPs and recombinant ECD, cAMP functional assays, epitope mapping\",\n      \"journal\": \"mAbs\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple selection strategies with functional cAMP assays and epitope mapping; single lab\",\n      \"pmids\": [\"27211075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Tetraspanin CD9 is upregulated upon GCGR activation in liver; CD9 deficiency exacerbated hepatic steatosis via complement factor D (CFD)-regulated fatty acid metabolism through ubiquitination-proteasomal degradation of FLI1; blockage of CD9 abolished the remission of hepatic steatosis induced by cotadutide (GCGR/GLP-1R dual agonist) treatment, identifying CD9 as a mediator of GCGR's hepatic effects.\",\n      \"method\": \"GCGR agonist treatment, CD9 liver-specific knockdown/overexpression, cotadutide pharmacological studies, mechanistic dissection of CFD/FLI1/ubiquitination pathway\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological plus genetic loss-of-function with defined downstream pathway, single lab\",\n      \"pmids\": [\"38837628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Interruption of glucagon signaling (GCGR antagonism/knockout) stimulated delta cell proliferation in mouse and transplanted human islets via SLC7A2 (cationic amino acid transporter) and mTORC1-dependent amino acid sensing mechanisms; beta cell proliferation was also augmented by gcgr deficiency via SLC7A2- and mTORC1-dependent mechanisms in zebrafish.\",\n      \"method\": \"Genetic epistasis using six models of interrupted glucagon signaling (zebrafish, rodents, transplanted human islets), global SLC7A2 deficiency, rapamycin-mediated mTORC1 inhibition; cell proliferation assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis across multiple model systems with mTOR inhibition rescue; preprint\",\n      \"pmids\": [\"bio_10.1101_2024.08.06.606926\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RACK1 scaffolding protein directly binds GCGR, PKA regulatory subunit RIIα, PKA catalytic subunit PKAcα, and CREB, assembling GCGR-PKA complexes at the plasma membrane and PKAcα-CREB complexes in the nucleus; acute hepatic RACK1 deficiency impaired PKAcα translocation, CREB phosphorylation, gluconeogenic gene expression, and caused fasting hypoglycemia; these defects were rescued by constitutively active PKAcα, placing RACK1 as a dual-compartment scaffold organizing the GCGR-PKA-CREB axis for hepatic gluconeogenesis.\",\n      \"method\": \"Acute hepatic RACK1 deletion in mice; co-immunoprecipitation; GST pulldown; proximity ligation assays; subcellular fractionation; confocal microscopy; metabolic tolerance tests; functional rescue with constitutively active PKAcα W196R\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal protein interaction methods plus genetic rescue; preprint, single lab\",\n      \"pmids\": [\"bio_10.1101_2025.06.18.660434\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Ligand-induced β-arrestin recruitment to GCGR proceeds in a phosphorylation-independent manner, in contrast to GLP-1R and GIPR where phosphorylation of C-terminal tail residues is a critical determinant driving β-arrestin complex formation; mutagenesis of identified phosphorylated residues had unique effects on βarr recruitment and cAMP production in a receptor-dependent manner.\",\n      \"method\": \"Proteomic identification of phosphorylated C-tail residues by mass spectrometry upon agonist addition; mutagenesis of phospho-residues; β-arrestin recruitment assays; cAMP production assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — mass spectrometry-identified PTMs with mutagenesis and functional assays; preprint, single lab\",\n      \"pmids\": [\"bio_10.1101_2025.03.10.642457\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Hepatic GCGR is required for the superior weight loss and lipid clearance effects of dual GCGR/GLP1R agonist BI 456908 compared to selective GLP-1R agonist semaglutide, as demonstrated using liver-specific receptor engagement studies; hepatic GCGR activation facilitates plasma and liver lipid clearance.\",\n      \"method\": \"Comparative pharmacological studies with dual GCGR/GLP1R agonist vs selective GLP-1R agonist in obese mice; liver-specific engagement assays; lipid and metabolic phenotyping\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological comparison with hepatic-specific engagement readouts; preprint\",\n      \"pmids\": [\"bio_10.1101_2024.09.09.611134\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"GCGR agonism recruits GABAergic signaling in the medial basal hypothalamus to promote UCP1-dependent thermogenesis in adipose tissue; weight loss from chronic GCGR agonism is primarily due to augmented metabolic rate rather than food intake reduction; this reveals a liver→brain→fat axis activated by GCGR agonism.\",\n      \"method\": \"Chronic treatment with long-acting GCGR agonist in obese mice; metabolic cage studies; mechanistic studies of hypothalamic GABAergic signaling and adipose tissue UCP1 expression\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo pharmacology with mechanistic pathway dissection; single lab\",\n      \"pmids\": [\"41654017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Avian GCGR is highly expressed in adipocytes (unlike mammalian GCGR) and employs a unique rapid fat utilization mechanism; expression of avian GCGR or constitutively active human GCGR variant (H339R) in white adipose tissue of obese male mice effectively promoted fat mobilization and sustained body weight loss.\",\n      \"method\": \"Cross-species single-nucleus RNA-sequencing; transgenic expression of avian GCGR or constitutively active human GCGR H339R in mouse white adipose tissue; metabolic phenotyping\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cross-species genomics combined with transgenic gain-of-function in mice with metabolic phenotyping; single lab\",\n      \"pmids\": [\"41315395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Activating GcgR (or Glp1R) with chemical agonists induces microtubule destabilization in β-cells in the absence of high glucose; inhibiting GcgR or Glp1R with antagonists attenuates high glucose-induced microtubule destabilization; this paracrine mechanism by which α-cell glucagon tunes β-cell insulin secretory granule availability through microtubule remodeling depends on GCGR signaling.\",\n      \"method\": \"Chemical agonist/antagonist studies in isolated mouse and human islets; live-cell microtubule imaging; GSIS assays in islets with varying α/β cell ratios\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological agonist/antagonist studies without genetic confirmation; preprint\",\n      \"pmids\": [\"bio_10.1101_2024.10.21.619544\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The V369M mutation in mouse GCGR (equivalent to human V368M) resulted in hyperglucagonemia, pancreas enlargement, α-cell hyperplasia, and increased plasma amino acid levels; on high-fat diet, ketogenic/glucogenic amino acid accumulation was particularly pronounced, consistent with GCGR's role in glucagon-mediated amino acid catabolism via a liver-α-cell axis.\",\n      \"method\": \"GcgrV369M+/+ knock-in mice; plasma amino acid profiling; pancreatic histology\",\n      \"journal\": \"Bioscience reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knock-in mouse model with defined metabolic readouts; single lab\",\n      \"pmids\": [\"34002801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Glucagon promotes gluconeogenesis through a GCGR/PKA/CREB/PGC-1α pathway in hepatocytes, as demonstrated by sequential inhibitor studies showing each step is required for glucagon-stimulated glucose production and gluconeogenic gene expression.\",\n      \"method\": \"Primary hepatocyte culture with GCGR inhibitor, PKA inhibitor, CREB inhibitor, PGC-1α inhibitor; gcgr gene overexpression; mRNA expression of downstream genes; glucose production assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological epistasis at each pathway node with genetic overexpression confirmation in primary cells; however in fish hepatocytes (orthologous pathway)\",\n      \"pmids\": [\"37048171\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GCGR is a class B1 G protein-coupled receptor that, upon glucagon binding at its extracellular domain and transmembrane domain surface, couples to Gs protein to elevate cAMP via adenylyl cyclase (including AC5 in β-cells), activating a PKA/CREB/PGC-1α axis—scaffolded by RACK1—to drive hepatic gluconeogenesis, amino acid catabolism, fatty acid oxidation, and lipid clearance; β-arrestin recruitment to GCGR occurs in a phosphorylation-independent manner (unlike GLP-1R); in β-cells, GCGR activation potentiates insulin secretion at physiological glucose via AC5-mediated cAMP; GCGR agonism in adipose tissue and via hypothalamic GABAergic/UCP1-dependent thermogenesis promotes energy expenditure, while complete loss of GCGR signaling in liver abolishes these metabolic programs and causes compensatory α-cell hyperplasia through SLC7A2/mTORC1-dependent mechanisms.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries from KEPT papers only.\n\n**EXCLUDED papers:**\n- [11] (retrieved corpus): GC/GR = glucocorticoid receptor, not GCGR\n- [20] (retrieved corpus): GC/GR = glucocorticoid receptor\n- [28] (retrieved corpus): GGR = glycine-glycine-arginine tripeptide MS study\n- [34] (retrieved corpus): GC/GR = glucocorticoid receptor\n- [52] (retrieved corpus): Glioblastoma/Hsp90 - no relation to GCGR\n- [59] (retrieved corpus): FAK/MEK glioblastoma - no relation to GCGR\n- Gene2pubmed [1],[2],[3],[5],[6],[8],[18],[19],[20]: cDNA libraries, interactomes, GO annotations, BMPR-II, midbody - not GCGR-specific\n- Gene2pubmed [18]: General GPCR review, not GCGR-specific mechanism\n\n**KEPT papers:** All remaining papers describing the canonical glucagon receptor (GCGR) protein.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"The human glucagon receptor (GCGR) was cloned from a liver cDNA library; it encodes a 477-amino-acid seven-transmembrane G protein-coupled receptor that, when transfected into COS-7 cells, confers high-affinity [125I]glucagon binding and transduces signals leading to increases in intracellular cAMP. Rank-order potency of binding: glucagon > oxyntomodulin > GLP-1(7-36) amide >> GLP-2 = GIP = secretin.\",\n      \"method\": \"cDNA cloning, heterologous expression in COS-7 cells, radioligand binding assay, cAMP measurement\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — functional receptor reconstitution in heterologous cells with ligand binding and cAMP signaling validated; foundational cloning paper\",\n      \"pmids\": [\"7507321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The GCGR gene maps to human chromosome 17q25, spans >5.5 kb with 12 introns, and encodes a receptor with 80% identity to rat GCGR. The cDNA-expressed receptor binds glucagon and signals via intracellular cAMP elevation.\",\n      \"method\": \"cDNA cloning from liver library, Southern blot, in situ hybridization to metaphase chromosomes, cAMP assay\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct genomic characterization and functional validation in expressing cells\",\n      \"pmids\": [\"8144028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A missense mutation Gly40Ser in GCGR is associated with NIDDM; receptor binding studies in cultured cells expressing this mutant show approximately three-fold lower glucagon-binding affinity compared to wild-type, establishing a functional consequence of this variant.\",\n      \"method\": \"Site-directed mutagenesis, radioligand binding assay in transfected cells, genetic association study\",\n      \"journal\": \"Nature Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct functional binding assay in expressing cells combined with genetic association; replicated in disease context\",\n      \"pmids\": [\"7773293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Three distinct epitopes on the extracellular face of the GCGR transmembrane core domain (at extracellular ends of TM2 and TM7, and the second extracellular loop/proximal TM4-TM5) determine specificity for the N-terminus of glucagon (residues Ser2, Gln3, Tyr10, Lys12). The N-terminal extracellular domain (ECD) determines specificity for the glucagon C-terminus, establishing a two-site binding model.\",\n      \"method\": \"Site-directed mutagenesis of receptor core domain, chimeric receptor construction, radioligand binding, cAMP functional assay\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with multiple orthogonal readouts defining specific receptor-ligand contacts\",\n      \"pmids\": [\"12724331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Glucagon acting through GCGR promotes hepatic glucose output by stimulating glycogenolysis and gluconeogenesis, and inhibiting glycogenesis and glycolysis. In diabetic states, hyperglucagonemia and altered insulin-to-glucagon ratios contribute to hyperglycemia through excessive hepatic glucose production via GCGR.\",\n      \"method\": \"In vivo animal models and human physiological studies (review synthesizing mechanistic data)\",\n      \"journal\": \"American Journal of Physiology. Endocrinology and Metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — synthesis of established in vivo mechanistic studies; role in hepatic glucose regulation well established across multiple experimental systems\",\n      \"pmids\": [\"12626323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Crystal structure of the seven-transmembrane helical domain of human GCGR resolved at 3.4 Å. The structure reveals a large ligand-binding pocket and a unique 'stalk' region extending three alpha-helical turns above the membrane plane on TM1, which positions the extracellular domain (~12 kDa) to form the glucagon-binding site. The ECD facilitates capture of glucagon peptide, enabling insertion of the glucagon N-terminus into the 7TM domain. Extensive site-specific mutagenesis and a hybrid glucagon-bound GCGR model provided molecular details of ligand recognition.\",\n      \"method\": \"X-ray crystallography (3.4 Å), site-directed mutagenesis, hybrid structural modeling\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus extensive mutagenesis; foundational structural paper replicated and extended by subsequent structures\",\n      \"pmids\": [\"23863937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Oxyntomodulin activates both GCGR and GLP-1R; simultaneous activation of both receptors reduces food intake and increases energy expenditure, with GLP-1R agonism counteracting the hyperglycemic effect of GCGR activation. This dual mechanism results in superior body weight lowering compared to selective GLP-1R agonism.\",\n      \"method\": \"In vivo pharmacological studies; human infusion studies; cell-based cAMP assays\",\n      \"journal\": \"Molecular Metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pharmacology studies in vivo and in vitro across multiple groups\",\n      \"pmids\": [\"24749050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Full-length GCGR can adopt open and closed conformations involving extensive contacts between the ECD and 7TM domain. Molecular dynamics and disulfide crosslinking studies indicate that apo-GCGR exists in both conformations, and peptide ligand binding (plus a monoclonal antibody) stabilizes an open/elongated conformation consistent with a conformational selection mechanism for glucagon binding. HDX studies identified the stalk and first extracellular loop as key modulators of peptide binding.\",\n      \"method\": \"Molecular dynamics simulations, disulfide crosslinking, electron microscopy, hydrogen/deuterium exchange (HDX), crystal structure of TMD\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (MD, crosslinking, EM, HDX) in single study with functional validation\",\n      \"pmids\": [\"26227798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Loss-of-function GCGR germline mutations (including homozygous stop mutations and compound heterozygous missense mutations) cause glucagon cell adenomatosis (GCA) — multifocal hyperplastic/neoplastic disease of pancreatic glucagon cells. By interrupting GCGR signaling, mutations drive glucagon cell hyperplasia and neoplasia, with mutation carriers exhibiting greater numbers and larger tumors than wild-type patients.\",\n      \"method\": \"Sanger and next-generation sequencing of all GCGR exons, clinicopathological correlation, genotyping in 2560 controls\",\n      \"journal\": \"The Journal of Clinical Endocrinology and Metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function mutations with defined cellular phenotype (glucagon cell hyperplasia/neoplasia); mechanistic link to interrupted GCGR signaling established\",\n      \"pmids\": [\"25695890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The small-molecule GCGR antagonist MK-0893 binds to an allosteric extra-helical site located between TM6 and TM7 extending into the lipid bilayer, outside the canonical 7TM bundle. This binding prevents the outward movement of TM6 required for G-protein coupling, thereby blocking receptor activation. Key residues at this novel site were confirmed by mutagenesis.\",\n      \"method\": \"X-ray crystallography (2.5 Å resolution of GCGR-MK-0893 complex), site-directed mutagenesis, functional cAMP assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure plus mutagenesis confirming allosteric binding site and mechanism of inhibition\",\n      \"pmids\": [\"27111510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The ECD of GCGR is strictly required for receptor activation even when the peptide hormone is covalently linked to the TMD, unlike some other class B GPCRs (e.g., CRF1R, PTH1R, PAC1R) where ECD requirement can be bypassed. This demonstrates that the GCGR ECD plays a direct, active role in signaling beyond merely serving as an affinity trap.\",\n      \"method\": \"Chimeric receptor construction, covalent peptide-TMD linkage experiments, cAMP functional assays\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct mechanistic experiment with covalent tethering and functional assays establishing active role of ECD\",\n      \"pmids\": [\"27226600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of full-length GCGR at 3.0 Å in inactive conformation reveals the stalk connecting the ECD and TMD adopts a β-strand conformation (not α-helix). The first extracellular loop (ECL1) forms a β-hairpin that interacts with the stalk to create a compact β-sheet structure. HDX, disulfide crosslinking and MD studies demonstrate that the stalk and ECL1 have critical roles in modulating peptide ligand binding and receptor activation.\",\n      \"method\": \"X-ray crystallography (3.0 Å, full-length), hydrogen-deuterium exchange, disulfide crosslinking, molecular dynamics\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — full-length crystal structure plus multiple orthogonal mechanistic validation methods\",\n      \"pmids\": [\"28514451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structure of full-length GCGR in complex with glucagon analogue NNC1702 at 3.0 Å reveals the molecular details of peptide-receptor interactions. The stalk and ECL1 undergo major conformational changes (secondary structure rearrangements) during peptide binding, forming key contacts with the peptide. The ECD-TMD relative orientation changes markedly relative to the inactive structure. A 'dual-binding-site trigger model' is proposed for GCGR activation requiring conformational changes in the stalk, ECL1, and TMD.\",\n      \"method\": \"X-ray crystallography (3.0 Å, full-length GCGR-peptide complex), structural comparison\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure of active-state ligand complex defining molecular activation mechanism\",\n      \"pmids\": [\"29300013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Complete ablation of hepatic glucagon receptor function in Gcgr-/- mice causes major metabolic alterations: significant down-regulation of gluconeogenesis, amino acid catabolism, and fatty acid oxidation, with up-regulation of glycolysis, fatty acid synthesis, and cholesterol biosynthesis. Plasma metabolite changes include decreased glucose and glucose-derived metabolites, and increased amino acids, cholesterol, and bile acids.\",\n      \"method\": \"Global Gcgr knockout mouse model, liver transcriptomics (Affymetrix arrays), liver proteomics (iTRAQ), plasma metabolite profiling (~200 analytes, mass spectrometry), pathway analysis\",\n      \"journal\": \"BMC Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic knockout with tri-omic profiling providing comprehensive mechanistic pathway placement; strong evidence from multiple orthogonal datasets\",\n      \"pmids\": [\"21631939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"GRA1, a small-molecule GCGR antagonist, blocks glucagon binding to human GCGR and antagonizes glucagon-induced cAMP accumulation with nanomolar potency. It inhibits glycogenolysis in primary human hepatocytes and perfused liver from humanized GCGR mice. In monkeys, GRA1 treatment down-regulates hepatic genes involved in amino acid catabolism and increases circulating amino acids, demonstrating GCGR's role in hepatic amino acid metabolism.\",\n      \"method\": \"In vitro cAMP assay, radioligand competition binding, primary human hepatocyte glycogenolysis assay, perfused liver from hGCGR transgenic mice, in vivo glucose tolerance in rodents and primates, hepatic gene-expression profiling\",\n      \"journal\": \"PLoS One\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal in vitro and in vivo methods in humanized model and primates; mechanistic link to amino acid metabolism established\",\n      \"pmids\": [\"23185367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In Gcgr-/- mice, GLP-2 receptor (GLP-2R) signaling controls circulating bile acid levels and their relative species proportions but is not essential for body weight control or glucose homeostasis. Gpbar1 (TGR5) does not mediate elevated proglucagon-derived peptide levels or major metabolic phenotypes in Gcgr-/- mice despite elevated bile acids. Small bowel growth in Gcgr-/- mice requires intact GLP-2R signaling.\",\n      \"method\": \"Double-knockout mouse models (Gcgr-/-:Gpbar1-/-, Gcgr-/-:Glp2r-/-), glucose tolerance testing, insulin measurement, bile acid profiling, intestinal mass measurement\",\n      \"journal\": \"Molecular Metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis via double-knockout mice with multiple metabolic phenotypic readouts\",\n      \"pmids\": [\"29937214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Computational free-energy landscape analysis reveals that GCGR activation follows a combined mechanism: the agonist (glucagon) first stabilizes the receptor in a 'pre-activated' state, which is then fully activated upon G protein binding — contrasting with the classical model of agonist-driven TM6 opening. This mechanism is consistent with cryo-EM structural data.\",\n      \"method\": \"Free-energy landscape computation (molecular dynamics simulations), comparison with cryo-EM structural data\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — computational with structural validation, but single study; mechanistic model not yet confirmed by independent mutagenesis\",\n      \"pmids\": [\"32571939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cryo-EM structures of GCGR bound to glucagon in complex with either Gs or Gi1 heterotrimeric G proteins reveal that both Gs and Gi1 bind in a similar open intracellular cavity. GCGR's Gs-binding selectivity is explained by a larger interaction interface with Gs; specific intracellular loop conformational differences are key selectivity determinants. Mutagenesis of identified residues confirmed their roles in transducer engagement.\",\n      \"method\": \"Cryo-electron microscopy structural determination, site-directed mutagenesis, functional G protein coupling assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structures of two distinct GCGR-G protein complexes plus mutagenesis validation\",\n      \"pmids\": [\"32193322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Glucagon potentiates glucose-stimulated insulin secretion (GSIS) via β-cell GCGR at physiological but not high glucose concentrations. GCGR activation elevates cAMP via adenylyl cyclase 5 (AC5) in β-cells, independently of high-glucose-induced cAMP elevation via the same AC5. High glucose concentration bypasses the GCGR requirement for cAMP elevation and insulin secretion. β-cell-specific GCGR knockout mice develop more severe glucose intolerance on high-fat diet.\",\n      \"method\": \"GCGR/GLP-1R antagonists in single β-cells, α-β cell clusters, and isolated islets; RAB-ICUE cAMP fluorescence indicator; specific AC family inhibitors; β-cell-specific GCGR knockout mice; high-fat diet metabolic phenotyping\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (live-cell imaging, pharmacological inhibition, cell-specific knockout) in same study\",\n      \"pmids\": [\"34572144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Ligand-specific reduction of β-arrestin-2 recruitment at GCGR (via partial agonism of OXM-derived co-agonists) slows GLP-1R internalization and prolongs glucose-lowering action in vivo, while retaining GCGR-mediated weight loss via increased energy expenditure. This establishes that GCGR co-agonism contributes weight loss through energy expenditure mechanisms distinct from food intake suppression.\",\n      \"method\": \"Cell-based β-arrestin-2 recruitment assays, receptor internalization assays, molecular dynamics simulations, in vivo glucose homeostasis and weight loss studies in mice\",\n      \"journal\": \"Molecular Metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cellular signaling assays plus in vivo validation; mechanism of β-arrestin-2-dependent GLP-1R internalization established\",\n      \"pmids\": [\"33933675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"19F-NMR studies of detergent-reconstituted GCGR in micelles and nanodiscs reveal that the negative allosteric modulator NNC0640 binding to the GCGR transmembrane domain confers the long-time stability required for NMR experiments, and produces distinct allosteric effects on receptor dynamics detectable via 19F probes on indigenous cysteines.\",\n      \"method\": \"19F-NMR spectroscopy, paramagnetic relaxation enhancement, detergent/nanodisc reconstitution, post-translational chemical labeling\",\n      \"journal\": \"The FEBS Journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — solution NMR with site-specific labeling; novel conformational dynamics data, single study\",\n      \"pmids\": [\"33369025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structures of GLP-1R and GCGR each in complex with Gs protein and three different dual GLP-1R/GCGR agonists (peptide 15, cotadutide/MEDI0382, SAR425899) reveal that distinct side chain orientations within the first three peptide residues determine receptor selectivity. The middle region of dual agonists engages ECL1, ECL2, and top of TM1, causing specific conformational changes; dual agonists reshape ECL1 conformation of GLP-1R relative to GCGR. Lipid moiety of MEDI0382 interacts with TM1-TM2 cleft of GCGR, explaining its increased potency at GCGR.\",\n      \"method\": \"Cryo-electron microscopy (high-resolution), structural analysis of multiple agonist-receptor-Gs complexes, pharmacological validation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple cryo-EM structures with pharmacological validation defining molecular basis of dual agonism\",\n      \"pmids\": [\"37549266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Super-resolution dSTORM imaging of HepG2 cells reveals that GCGR forms nanoscale clusters on the plasma membrane. High glucose promotes increased GCGR expression and formation of larger, more numerous clusters. Under high glucose, glucagon stimulation fails to suppress GCGR cluster levels or increase downstream cAMP-PKA signaling, demonstrating that high glucose induces glucagon resistance at the receptor level. Hepatoma cells display stronger glucagon resistance than normal hepatic cells under high glucose.\",\n      \"method\": \"Direct stochastic optical reconstruction microscopy (dSTORM), cAMP-PKA signaling assays, GCGR expression quantification in HepG2 vs. primary hepatic cells\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct super-resolution localization imaging with functional signaling readout; novel mechanistic link between GCGR membrane clustering and glucagon resistance\",\n      \"pmids\": [\"36824278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GLP-1 selectively binds the extracellular surface of GLP-1R transmembrane domain (TMD) even in the absence of the ECD, as shown by paramagnetic NMR. Cross-reactivity of GLP-1R with glucagon and GCGR with GLP-1 was demonstrated, providing molecular evidence of receptor cross-reactivity in solution relevant to dual agonist pharmacology.\",\n      \"method\": \"Paramagnetic NMR relaxation enhancement, dual 19F/nitroxide spin labeling of receptor and peptide ligands, solution-state measurements of GLP-1R-TMD and GCGR\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — NMR with site-specific labeling providing direct evidence of binding site and cross-reactivity; single study\",\n      \"pmids\": [\"37332600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In Japanese flounder hepatocytes, glucagon promotes gluconeogenesis through a defined GCGR/PKA/CREB/PGC-1α pathway: GCGR activation increases Gs/adenylyl cyclase activity, elevating cAMP, which activates PKA to phosphorylate CREB, which induces PGC-1α expression, leading to upregulation of gluconeogenic genes pck1 and g6pc and glucose production. Each step was validated by specific inhibitors and GCGR overexpression.\",\n      \"method\": \"Primary hepatocyte culture, pharmacological inhibitors of GCGR/PKA/CREB/PGC-1α, gcgr gene overexpression, mRNA/protein quantification, glucose production assay\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic pharmacological dissection with overexpression rescue in fish hepatocytes; consistent with mammalian GCGR pathway\",\n      \"pmids\": [\"37048171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structures of human GLP-1R, GCGR, and GIPR in complex with Gs proteins in the absence of cognate ligands reveal that Gs protein alone directly opens the intracellular binding cavity and rewires the extracellular orthosteric pocket. In ligand-free GCGR, a segment of ECL2 partially occupies the peptide-binding site. These ligand-free structures demonstrate that Gs protein can mobilize the intracellular transmembrane domain and rearrange the extracellular region to a transitional conformation facilitating peptide N-terminus entry.\",\n      \"method\": \"Cryo-electron microscopy (high-resolution), structural comparison of ligand-free vs. ligand-bound receptor-Gs complexes\",\n      \"journal\": \"Cell Discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution cryo-EM structures with detailed structural analysis defining G protein-driven receptor activation mechanism\",\n      \"pmids\": [\"38346960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ALKBH5, an RNA m6A demethylase, is phosphorylated by protein kinase A (PKA), causing its translocation from the nucleus to the cytosol. Hepatocyte-specific Alkbh5 deletion inhibits GCGR signaling pathways and reduces glucose and lipid levels. ALKBH5 regulates glucose homeostasis through the GCGR pathway and lipid homeostasis through mTORC1, establishing ALKBH5 as a regulator upstream of GCGR-mediated metabolic signaling.\",\n      \"method\": \"Hepatocyte-specific conditional knockout, PKA phosphorylation assays, metabolic phenotyping (glucose/lipid measurements), pathway analysis\",\n      \"journal\": \"Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional hepatic KO with metabolic phenotyping establishing ALKBH5-GCGR regulatory relationship; single study\",\n      \"pmids\": [\"40014709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CD9 (tetraspanin) mediates hepatic effects of GCGR agonism. GCGR activation upregulates hepatic CD9 expression. CD9 deficiency exacerbates diet-induced hepatic steatosis via complement factor D (CFD)-regulated fatty acid metabolism; CD9 modulates hepatic fatty acid synthesis and oxidation genes through regulating CFD expression via ubiquitination-proteasomal degradation of FLI1. Blockade of CD9 abolishes cotadutide (GCGR/GLP-1R agonist)-induced remission of hepatic steatosis.\",\n      \"method\": \"Hepatic CD9 knockdown/knockout, GCGR agonist treatment (cotadutide), ubiquitination assays, adipose thermogenesis measurement, hepatic gene expression\",\n      \"journal\": \"Advanced Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway from GCGR to CD9/CFD/FLI1 established with KO and rescue experiments; single study\",\n      \"pmids\": [\"38837628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Downregulation of GCGR and GLP1R in stenotic ileum of Crohn's disease patients and fibrotic mouse colon leads to accumulation of metabolic lactate, resulting in histone H3K9 lactylation in epithelial cells and epithelial-to-mesenchymal transition (EMT)-driven intestinal fibrosis. Dual GCGR/GLP1R activation by peptide 1907B reduces H3K9 lactylation and ameliorates intestinal fibrosis in vivo, establishing GCGR's role in regulating epithelial energy metabolism and EMT.\",\n      \"method\": \"Patient tissue analysis, chronic colitis mouse model, histone lactylation assays, EMT marker analysis, dual agonist treatment in vivo\",\n      \"journal\": \"Acta Pharmaceutica Sinica B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway linking GCGR signaling to lactate/histone lactylation/EMT established with in vivo validation; single study\",\n      \"pmids\": [\"40041889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Hepatic GCGR is the critical mediator of superior weight loss and lipid clearance achieved by the dual GCGR/GLP1R agonist BI 456908 compared to selective GLP1R agonism. Hepatic GCGR engagement facilitates plasma and liver lipid clearance, demonstrating a direct hepatic GCGR contribution to the metabolic efficacy of dual agonism.\",\n      \"method\": \"Comparison of dual agonist (BI 456908) vs. selective GLP1R agonist (semaglutide) in vivo; liver-specific mechanistic assessment; body weight and lipid profiling\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 2-3 — preprint; pharmacological dissection without genetic confirmation of hepatic GCGR specificity\",\n      \"pmids\": [\"bio_10.1101_2024.09.09.611134\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RACK1 (Receptor for Activated C Kinase 1) functions as a dual-compartment scaffold for the hepatic glucagon-PKA-CREB signaling axis. RACK1 directly binds GCGR, PKA regulatory (RIIα) and catalytic (PKAcα) subunits, and CREB, assembling GCGR-PKA complexes at the plasma membrane and PKAcα-CREB complexes in the nucleus. Loss of hepatic RACK1 impairs PKAcα translocation, CREB phosphorylation, and gluconeogenic gene expression, causing fasting hypoglycemia. These defects are rescued by constitutively active PKAcα.\",\n      \"method\": \"Acute hepatic RACK1 deletion (mouse liver), co-immunoprecipitation, GST pulldown, proximity ligation assay, confocal microscopy, cell fractionation, glucose/pyruvate tolerance tests, hepatocyte glucose production assay, PKAcα W196R rescue experiment\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (Co-IP, GST pulldown, PLA, imaging, fractionation) with genetic rescue; preprint status limits confidence\",\n      \"pmids\": [\"bio_10.1101_2025.06.18.660434\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GCGR agonism in obese mice recruits GABAergic signaling in the medial basal hypothalamus to promote UCP1-dependent thermogenesis in adipose tissue, increase caloric expenditure, and drive negative energy balance. This establishes a liver→brain→fat axis for GCGR-mediated weight loss, with weight loss occurring primarily through augmented metabolic rate rather than food intake reduction.\",\n      \"method\": \"Chronic GCGR agonist treatment in obese mice, metabolic cage studies at room temperature and thermoneutrality, hypothalamic circuit manipulation (GABAergic signaling), UCP1 protein measurement in adipose tissue, body composition analysis\",\n      \"journal\": \"Molecular Metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined neural circuit mechanism with specific thermogenic readout; single study, not yet peer-reviewed in corpus but published\",\n      \"pmids\": [\"41654017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Ligand-induced β-arrestin recruitment to GCGR proceeds in a phosphorylation-independent manner, in contrast to GLP-1R and GIPR where phosphorylation of C-terminal tail residues is a critical determinant driving GPCR-β-arrestin complex formation. Mutagenesis of identified C-tail phosphorylation sites confirms unique receptor-specific effects on β-arrestin recruitment and cAMP production.\",\n      \"method\": \"Proteomic identification of C-tail phosphorylation sites (mass spectrometry), site-directed mutagenesis, β-arrestin recruitment assay, cAMP assay\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — proteomic identification plus mutagenesis with functional assays; preprint status limits confidence\",\n      \"pmids\": [\"bio_10.1101_2025.03.10.642457\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Interruption of glucagon signaling (via GCGR antagonism or Gcgr knockout) augments delta cell and beta cell proliferation in mouse, zebrafish, and transplanted human islets. This proliferative response requires the cationic amino acid transporter SLC7A2 and mTORC1 activation — established by rapamycin sensitivity and SLC7A2-deficient models — linking GCGR-mediated amino acid sensing to islet non-alpha cell growth.\",\n      \"method\": \"Multiple models (zebrafish gcgr deficiency, rodent GCGR antagonism/KO, transplanted human islets), rapamycin inhibition, SLC7A2 global knockout, delta/beta cell proliferation quantification\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established across six models with genetic and pharmacological confirmation of SLC7A2/mTORC1 requirement; preprint\",\n      \"pmids\": [\"bio_10.1101_2024.08.06.606926\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Avian GCGR is expressed at high levels in adipocytes (unlike mammalian GCGR which is minimally expressed in adipose). Avian GCGR or constitutively active human GCGR variant (GCGRH339R) expressed in white adipose tissue of obese male mice effectively promotes fat mobilization and sustained body weight loss, with decreased food intake partially contributing to weight reduction. This identifies adipose GCGR as a mechanism for continuous fat utilization.\",\n      \"method\": \"Cross-species single-nucleus RNA-sequencing, viral expression of avian GCGR and human GCGRH339R in mouse white adipose tissue, body composition and weight tracking, food intake measurement\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — snRNA-seq discovery with functional viral expression rescue in mouse adipose; novel adipose GCGR mechanism\",\n      \"pmids\": [\"41315395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Globally eliminating GCGR signaling (Gcgr KO) decreases median lifespan by 35% in lean mice and 54% in obese mice. Glucagon receptor signaling is indispensable for the metabolic benefits of caloric restriction: while CR reduces liver fat, serum triglycerides and cholesterol in wild-type mice, these benefits are absent in Gcgr KO mice. Liver-specific Gcgr deletion decreases hepatic AMPK activation in aging mice regardless of diet, and abolishes CR-mediated suppression of mTOR activity.\",\n      \"method\": \"Global and liver-specific Gcgr knockout mice, dietary manipulation (caloric restriction), metabolic phenotyping (liver fat, lipids), AMPK and mTOR activity measurements\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (global and liver-specific KO) with defined nutrient-sensing pathway readouts; preprint\",\n      \"pmids\": [\"bio_10.1101_2025.05.13.653849\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"GCGR is a class B GPCR expressed predominantly in liver, kidney, pancreatic islets, and other tissues that binds glucagon via a two-site mechanism (C-terminus to ECD, N-terminus to TMD binding pocket), requires its ECD as an active signaling participant, couples primarily to Gs (and secondarily Gi1) through intracellular loop contacts, activates the PKA/CREB/PGC-1α axis to drive hepatic gluconeogenesis (scaffolded by RACK1), promotes glycogenolysis, fatty acid oxidation, and amino acid catabolism in liver, stimulates cAMP via AC5 in pancreatic β-cells to potentiate insulin secretion, recruits β-arrestin in a phosphorylation-independent manner distinct from related receptors, and engages hypothalamic GABAergic circuits to drive UCP1-dependent thermogenesis in adipose tissue; loss-of-function mutations cause glucagon cell hyperplasia/neoplasia via interrupted feedback, while allosteric small-molecule antagonists bind an extra-helical TM6-TM7 site to prevent G protein coupling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"GCGR is a class B1 G protein-coupled receptor for glucagon that couples to Gs to activate a cAMP–PKA–CREB–PGC-1α signaling cascade—scaffolded by RACK1 at the plasma membrane and in the nucleus—driving hepatic gluconeogenesis, amino acid catabolism, fatty acid oxidation, and lipid clearance [PMID:21631939, PMID:37048171, PMID:38837628]. In pancreatic β-cells, GCGR activation potentiates glucose-stimulated insulin secretion at physiological glucose concentrations through adenylyl cyclase 5–mediated cAMP generation, and also promotes microtubule remodeling that tunes insulin granule availability [PMID:34572144]. Loss of GCGR signaling causes compensatory α- and δ-cell hyperplasia through SLC7A2/mTORC1-dependent amino acid sensing, and elevated circulating amino acids via disruption of the liver–α-cell axis [PMID:34002801]. GCGR agonism in adipose tissue promotes fat mobilization and, via a hypothalamic GABAergic/UCP1-dependent thermogenic circuit, augments energy expenditure to drive weight loss [PMID:41654017, PMID:41315395].\",\n  \"teleology\": [\n    {\n      \"year\": 2011,\n      \"claim\": \"Global loss of GCGR established that hepatic glucagon signaling is required for gluconeogenesis, amino acid catabolism, and fatty acid oxidation, while simultaneously suppressing lipogenesis and cholesterol synthesis—defining the full metabolic program downstream of GCGR in liver.\",\n      \"evidence\": \"Integrated transcriptomic, proteomic, and metabolomic profiling in Gcgr−/− versus wild-type mice\",\n      \"pmids\": [\"21631939\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Intracellular signaling intermediates connecting GCGR to each metabolic branch were not resolved\",\n        \"Contribution of extrahepatic GCGR signaling was not separated from hepatic effects\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identification of antagonistic antibodies targeting both the extracellular domain and extracellular loop epitopes of GCGR revealed that the ECD adopts a closed conformation shielding the ECLs, informing the structural basis for receptor accessibility and therapeutic antibody design.\",\n      \"evidence\": \"Llama DNA immunization, scFv phage display on VLPs and recombinant ECD, cAMP functional assays, and epitope mapping\",\n      \"pmids\": [\"27211075\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No high-resolution structure of the closed ECD conformation was obtained\",\n        \"In vivo efficacy and selectivity of ECL-targeting antibodies were not tested\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Genetic epistasis using compound Gcgr−/−:Glp2r−/− and Gcgr−/−:Gpbar1−/− knockouts dissected which phenotypes of GCGR loss are mediated by elevated proglucagon-derived peptides, showing GLP-2R drives bile acid and intestinal growth phenotypes but neither GLP-2R nor TGR5 accounts for the improved glucose tolerance of Gcgr−/− mice.\",\n      \"evidence\": \"Compound knockout mice with metabolic phenotyping including glucose tolerance, circulating hormone, and bile acid measurements\",\n      \"pmids\": [\"29937214\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The receptor(s) mediating improved glucose tolerance in Gcgr−/− mice remain unidentified\",\n        \"Direct hepatic versus islet contribution was not separated\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"GCGR on β-cells was shown to potentiate insulin secretion at physiological glucose via AC5-dependent cAMP, establishing a direct intra-islet paracrine glucagon–insulin axis independent of GLP-1R and revealing AC5 as a shared but independently activated node.\",\n      \"evidence\": \"β-cell-specific GCGR knockout mice, genetically encoded cAMP biosensor imaging, pharmacological AC inhibitors\",\n      \"pmids\": [\"34572144\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How AC5 integrates GCGR and glucose signals remains mechanistically unresolved\",\n        \"Relevance of this axis in human β-cells in situ was not directly demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A partial-loss-of-function GCGR knock-in mutation (V369M) recapitulated hyperglucagonemia, α-cell hyperplasia, and amino acid accumulation, confirming a liver–α-cell feedback axis governed by GCGR-dependent amino acid catabolism.\",\n      \"evidence\": \"GcgrV369M knock-in mice with plasma amino acid profiling and pancreatic histology\",\n      \"pmids\": [\"34002801\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The specific amino acid species or sensor mediating α-cell hyperplasia was not identified\",\n        \"Degree of residual GCGR signaling in V369M mutant not quantified\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Reduced β-arrestin-2 recruitment to GCGR by oxyntomodulin-derived co-agonists was linked to slower internalization and prolonged in vivo glucose lowering, indicating that partial agonism—not biased agonism—explains the superior therapeutic profile of dual GLP-1R/GCGR peptides.\",\n      \"evidence\": \"Cell-based β-arrestin-2 recruitment, internalization assays, molecular dynamics, and in vivo glucose/weight studies\",\n      \"pmids\": [\"33933675\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Contribution of GCGR versus GLP-1R to in vivo efficacy of dual agonists was not fully deconvolved\",\n        \"β-arrestin scaffolding functions beyond desensitization not assessed\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Cryo-EM structures of GCGR–Gs complexes with three dual GLP-1R/GCGR agonists resolved how the first three peptide residues and ECL1 conformations determine receptor selectivity, and how lipid moieties enhance GCGR potency by interacting with the TM1–TM2 cleft.\",\n      \"evidence\": \"Cryo-EM structures with pharmacological validation\",\n      \"pmids\": [\"37549266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Dynamics of ligand engagement and pathway activation kinetics were not captured\",\n        \"Structures of GCGR with biased or antagonist ligands remain unavailable\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"NMR solution studies demonstrated that glucagon engages the GCGR transmembrane domain extracellular surface even without the ECD, and that GCGR can cross-react with GLP-1, clarifying binding determinants in a native-like membrane environment.\",\n      \"evidence\": \"19F/nitroxide paramagnetic relaxation NMR on purified GCGR in nanodiscs\",\n      \"pmids\": [\"37332600\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Affinity quantification for GLP-1 at GCGR was not reported\",\n        \"Physiological relevance of GLP-1 cross-reactivity at GCGR is undefined\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The GCGR–PKA–CREB–PGC-1α signaling axis was ordered by sequential pharmacological inhibition in hepatocytes, establishing each node as individually required for glucagon-stimulated gluconeogenesis.\",\n      \"evidence\": \"Primary hepatocyte inhibitor epistasis and gcgr overexpression with glucose production and mRNA assays\",\n      \"pmids\": [\"37048171\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Demonstrated in fish hepatocytes; full validation in mammalian primary hepatocytes not shown\",\n        \"Scaffolding or compartmentalization of the signaling cascade was not addressed\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A ligand-free GCGR–Gs cryo-EM structure revealed that Gs protein alone can open the intracellular cavity and rearrange the extracellular pocket, with ECL2 partially occupying the peptide-binding site—demonstrating a G-protein-driven activation mechanism distinct from agonist-bound states.\",\n      \"evidence\": \"Cryo-EM structure of apo-GCGR in complex with Gs\",\n      \"pmids\": [\"38346960\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Physiological relevance of the ligand-free active state in vivo is unknown\",\n        \"Whether constitutive activity of GCGR proceeds through this state was not tested\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"CD9 was identified as a downstream mediator of hepatic GCGR activation that protects against steatosis via CFD-regulated fatty acid metabolism; loss of CD9 abolished the anti-steatotic effects of GCGR/GLP-1R dual agonism, revealing a previously unknown effector branch.\",\n      \"evidence\": \"GCGR agonist treatment, liver-specific CD9 knockdown/overexpression, cotadutide pharmacology, FLI1 ubiquitination pathway dissection\",\n      \"pmids\": [\"38837628\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which GCGR activation upregulates CD9 is not defined\",\n        \"Relative contribution of GCGR versus GLP-1R to CD9 induction in dual agonist setting is unclear\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Interruption of glucagon signaling stimulated δ-cell and β-cell proliferation through SLC7A2-dependent amino acid transport and mTORC1 activation, identifying the molecular sensor linking GCGR loss to islet cell hyperplasia across species.\",\n      \"evidence\": \"Six genetic models of interrupted glucagon signaling (zebrafish, rodent, human islet transplants), SLC7A2 deficiency, rapamycin rescue (preprint)\",\n      \"pmids\": [\"bio_10.1101_2024.08.06.606926\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Awaits peer review\",\n        \"Whether specific amino acids or total amino acid load drives mTORC1 activation was not resolved\",\n        \"Long-term consequences of islet cell hyperplasia not assessed\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"RACK1 was identified as a dual-compartment scaffold that organizes GCGR–PKA complexes at the plasma membrane and PKAcα–CREB complexes in the nucleus; acute hepatic RACK1 deletion caused fasting hypoglycemia rescued by constitutively active PKAcα, establishing RACK1 as essential for spatial organization of GCGR-dependent gluconeogenesis.\",\n      \"evidence\": \"Acute hepatic RACK1 deletion, co-IP, GST pulldown, proximity ligation, subcellular fractionation, PKAcα rescue (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.06.18.660434\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Awaits peer review\",\n        \"Structural basis of RACK1–GCGR interaction not determined\",\n        \"Whether RACK1 also scaffolds other GPCR–PKA cascades was not addressed\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"β-Arrestin recruitment to GCGR was shown to be phosphorylation-independent, contrasting with GLP-1R and GIPR where C-tail phosphorylation is critical, revealing receptor-specific desensitization logic among incretin-family GPCRs.\",\n      \"evidence\": \"Mass spectrometry identification of phosphorylated C-tail residues, site-directed mutagenesis, β-arrestin recruitment and cAMP assays (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.03.10.642457\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Awaits peer review\",\n        \"Alternative determinants driving phosphorylation-independent β-arrestin binding to GCGR not identified\",\n        \"In vivo consequences of phospho-independent arrestin recruitment not tested\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Cross-species analysis revealed high adipocyte expression of avian GCGR, and transgenic expression of avian or constitutively active human GCGR (H339R) in mouse white adipose tissue promoted fat mobilization and sustained weight loss, establishing adipose GCGR as a direct effector of fat utilization.\",\n      \"evidence\": \"Single-nucleus RNA-seq across species, transgenic adipose GCGR expression in obese mice, metabolic phenotyping\",\n      \"pmids\": [\"41315395\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Downstream lipolytic effectors activated by adipose GCGR not fully characterized\",\n        \"Whether human adipose GCGR achieves similar effects at endogenous expression levels is untested\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"GCGR agonism was shown to augment energy expenditure through hypothalamic GABAergic signaling and UCP1-dependent adipose thermogenesis, defining a liver→brain→fat axis as the primary mechanism of GCGR-driven weight loss rather than appetite suppression.\",\n      \"evidence\": \"Chronic long-acting GCGR agonist in obese mice, metabolic cages, hypothalamic GABAergic signaling and adipose UCP1 studies\",\n      \"pmids\": [\"41654017\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Identity of the hepatic signal communicating to hypothalamus is unknown\",\n        \"Whether this thermogenic axis operates in humans has not been tested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The identity of the circulating signal(s) linking hepatic GCGR activation to hypothalamic GABAergic circuits, the structural basis of phosphorylation-independent β-arrestin recruitment, and the precise amino acid species sensed by SLC7A2/mTORC1 to drive islet cell hyperplasia remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Liver-to-brain signal mediating GCGR-dependent thermogenesis unidentified\",\n        \"No structural model of GCGR–β-arrestin complex exists\",\n        \"Specific amino acid(s) driving mTORC1-dependent α/δ-cell proliferation not defined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 2, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 8, 10, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 4, 6, 14, 20]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 11, 15, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 12, 19]}\n    ],\n    \"complexes\": [\n      \"GCGR–Gs heterotrimer\"\n    ],\n    \"partners\": [\n      \"GNAS\",\n      \"ARRB2\",\n      \"RACK1\",\n      \"ADCY5\",\n      \"CREB1\",\n      \"CD9\",\n      \"SLC7A2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"GCGR is a class B G protein-coupled receptor that serves as the principal mediator of glucagon's metabolic actions, coupling ligand binding to Gs-dependent cAMP elevation to drive hepatic gluconeogenesis, glycogenolysis, amino acid catabolism, and fatty acid oxidation [PMID:7507321, PMID:21631939, PMID:23185367]. Glucagon engages GCGR through a two-site mechanism in which the peptide C-terminus binds the extracellular domain (ECD) and the N-terminus inserts into the transmembrane domain (TMD) pocket, with the ECD playing an obligate active role in receptor activation beyond simple affinity capture; stalk and ECL1 conformational rearrangements trigger TMD opening for G protein engagement [PMID:12724331, PMID:27226600, PMID:29300013]. GCGR couples primarily to Gs and secondarily to Gi1 through a larger Gs interaction interface, recruits β-arrestin in a phosphorylation-independent manner distinct from related incretin receptors, and is inhibited by allosteric small-molecule antagonists that bind an extra-helical TM6–TM7 site to prevent TM6 outward movement [PMID:32193322, PMID:27111510, PMID:bio_10.1101_2025.03.10.642457]. Loss-of-function GCGR mutations cause glucagon cell adenomatosis characterized by multifocal α-cell hyperplasia and neoplasia due to interrupted glucagon feedback [PMID:25695890].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Molecular cloning of human GCGR from liver cDNA established it as a seven-transmembrane receptor that binds glucagon with high affinity and signals via cAMP, placing glucagon signaling within the GPCR superfamily and mapping the gene to chromosome 17q25.\",\n      \"evidence\": \"Heterologous expression in COS-7 cells with radioligand binding and cAMP assays; genomic Southern blot and in situ hybridization\",\n      \"pmids\": [\"7507321\", \"8144028\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural information on receptor architecture\", \"Downstream effectors beyond cAMP not identified\", \"Tissue-specific signaling differences not addressed\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of the Gly40Ser missense variant linked to NIDDM demonstrated that single amino acid changes in GCGR can reduce glucagon-binding affinity ~3-fold, establishing the receptor as a diabetes-relevant locus.\",\n      \"evidence\": \"Site-directed mutagenesis with radioligand binding in transfected cells combined with genetic association\",\n      \"pmids\": [\"7773293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling consequences of reduced affinity not measured\", \"Causal role vs. association not definitively resolved\", \"No structural basis for affinity loss\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Systematic mutagenesis and chimeric receptor studies defined the two-site binding model: the ECD captures the glucagon C-terminus while three distinct TMD epitopes recognize the glucagon N-terminus, providing the first molecular framework for ligand selectivity.\",\n      \"evidence\": \"Site-directed mutagenesis, chimeric receptors, radioligand binding and cAMP assays\",\n      \"pmids\": [\"12724331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No atomic-resolution structure to confirm predicted contacts\", \"Dynamics of binding transition not captured\", \"Mechanism of signaling transduction from binding to G protein engagement undefined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Global Gcgr knockout mice revealed the full metabolic scope of GCGR signaling: loss abolished hepatic gluconeogenesis and amino acid catabolism while upregulating glycolysis and lipogenesis, establishing GCGR as a master regulator of hepatic fuel selection.\",\n      \"evidence\": \"Gcgr-/- mouse with tri-omic profiling (transcriptomics, proteomics, metabolomics)\",\n      \"pmids\": [\"21631939\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-autonomous vs. systemic effects not dissected\", \"Compensatory hormonal changes (hyperglucagonemia, elevated GLP-1) confound interpretation\", \"Tissue-specific contributions not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"The first crystal structure of the GCGR TMD at 3.4 Å revealed a uniquely extended TM1 stalk that positions the ECD for glucagon capture, providing atomic-level understanding of the two-site binding mechanism and identifying the large orthosteric pocket.\",\n      \"evidence\": \"X-ray crystallography (3.4 Å) with extensive mutagenesis and hybrid modeling\",\n      \"pmids\": [\"23863937\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure captured only the TMD, not full-length receptor\", \"No agonist-bound conformation\", \"G protein coupling interface not visualized\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Loss-of-function GCGR germline mutations were shown to cause glucagon cell adenomatosis, directly linking interrupted glucagon feedback through GCGR to α-cell hyperplasia and neoplasia in humans.\",\n      \"evidence\": \"Sequencing of GCGR exons in GCA patients with clinicopathological correlation and control genotyping\",\n      \"pmids\": [\"25695890\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Precise mechanism by which absent signaling drives proliferation not defined\", \"Small patient cohort\", \"No functional reconstitution of identified mutations\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"The crystal structure of GCGR bound to MK-0893 revealed an unprecedented extra-helical allosteric antagonist site between TM6 and TM7 that blocks the TM6 outward movement required for G protein coupling, opening a new pharmacological modality for GCGR inhibition.\",\n      \"evidence\": \"X-ray crystallography (2.5 Å) of GCGR–MK-0893 complex with mutagenesis and cAMP assays\",\n      \"pmids\": [\"27111510\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other class B GPCRs share this site not established\", \"Effect on β-arrestin recruitment not tested\", \"In vivo relevance of allosteric inhibition mechanism not confirmed structurally\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Covalent tethering experiments demonstrated that the GCGR ECD is an obligate active participant in signal transduction rather than a passive affinity trap, distinguishing GCGR from other class B GPCRs where the ECD requirement can be bypassed.\",\n      \"evidence\": \"Covalent peptide–TMD linkage with chimeric receptors and cAMP assays\",\n      \"pmids\": [\"27226600\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for ECD's active signaling role not determined\", \"Which ECD residues mediate signaling vs. binding not dissected\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The full-length inactive GCGR structure revealed the stalk adopts a β-strand (not α-helical) conformation forming a β-sheet with ECL1, resolving the structural basis for ECD–TMD communication and identifying the stalk/ECL1 as a conformational switch controlling ligand access.\",\n      \"evidence\": \"X-ray crystallography (3.0 Å full-length), HDX, disulfide crosslinking, molecular dynamics\",\n      \"pmids\": [\"28514451\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Active-state full-length structure not yet available at this point\", \"Mechanism by which stalk rearrangement transmits signal to TMD not fully defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The crystal structure of GCGR bound to glucagon analogue NNC1702 captured the peptide-engaged state, showing that stalk and ECL1 undergo major secondary-structure rearrangements during activation and establishing a 'dual-binding-site trigger model' for class B GPCR activation.\",\n      \"evidence\": \"X-ray crystallography (3.0 Å, full-length GCGR–peptide complex)\",\n      \"pmids\": [\"29300013\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"G protein coupling geometry not captured in same structure\", \"Dynamics of transition from inactive to active not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Cryo-EM structures of GCGR–glucagon complexes with both Gs and Gi1 revealed the structural basis for G protein selectivity: Gs forms a larger interface with GCGR intracellular loops, explaining preferential Gs coupling while showing Gi1 engagement uses the same open cavity.\",\n      \"evidence\": \"Cryo-EM of two GCGR–G protein complexes with mutagenesis validation\",\n      \"pmids\": [\"32193322\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinetic basis for Gs preference over Gi not addressed\", \"βγ subunit contributions to selectivity not dissected\", \"Gq coupling not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"β-cell GCGR was shown to potentiate glucose-stimulated insulin secretion at physiological glucose via AC5-dependent cAMP elevation, with β-cell-specific GCGR knockout mice developing exacerbated glucose intolerance on high-fat diet, establishing a direct paracrine α→β cell glucagon circuit.\",\n      \"evidence\": \"Single β-cell and islet cAMP imaging, AC family inhibitors, β-cell-specific GCGR knockout mice\",\n      \"pmids\": [\"34572144\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of GCGR vs. GLP-1R in β-cell cAMP generation under physiological conditions not quantified\", \"Whether AC5 specificity is universal across species not confirmed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Multiple cryo-EM structures of GCGR with dual GLP-1R/GCGR agonists defined how the first three peptide residues determine receptor selectivity and how lipid moieties on agonists engage the TM1–TM2 cleft, providing a structural template for rational design of dual agonist therapeutics.\",\n      \"evidence\": \"Cryo-EM of three dual agonist–GCGR–Gs complexes with pharmacological validation\",\n      \"pmids\": [\"37549266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"β-arrestin-biased signaling by dual agonists not structurally characterized\", \"In vivo tissue-specific signaling outcomes of differential receptor engagement not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Ligand-free cryo-EM structures showed that Gs protein alone can open the GCGR intracellular cavity and partially remodel the extracellular peptide-binding site, with ECL2 occupying the orthosteric pocket in the absence of peptide — demonstrating that G protein pre-coupling creates a transitional state facilitating agonist entry.\",\n      \"evidence\": \"Cryo-EM of ligand-free GCGR–Gs complex with structural comparison to ligand-bound states\",\n      \"pmids\": [\"38346960\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of ligand-free G protein pre-coupling not established in cells\", \"Whether this mechanism operates for Gi coupling not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"GCGR blockade was shown to drive δ-cell and β-cell proliferation through SLC7A2-dependent amino acid transport and mTORC1 activation, linking GCGR-regulated amino acid homeostasis to islet cell mass expansion across zebrafish, mouse, and human islet models.\",\n      \"evidence\": \"Multi-species models (zebrafish, rodent KO/antagonism, transplanted human islets), rapamycin inhibition, SLC7A2 knockout (preprint)\",\n      \"pmids\": [\"bio_10.1101_2024.08.06.606926\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Not peer-reviewed\", \"Mechanism by which elevated amino acids activate mTORC1 specifically in δ/β cells not defined\", \"Long-term consequences of proliferation not assessed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"RACK1 was identified as a dual-compartment scaffold that physically links GCGR to PKA subunits at the plasma membrane and PKAcα to CREB in the nucleus, with hepatic RACK1 deletion causing fasting hypoglycemia reversible by constitutively active PKAcα — establishing the first scaffolding mechanism for spatial organization of the glucagon–PKA–CREB cascade.\",\n      \"evidence\": \"Hepatic RACK1 deletion, co-IP, GST pulldown, proximity ligation assay, cell fractionation, PKAcα rescue (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.06.18.660434\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Not peer-reviewed\", \"Whether RACK1 scaffolding is GCGR-specific or shared with other Gs-coupled receptors not tested\", \"Structural basis for RACK1–GCGR interaction not resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"GCGR agonism was shown to engage hypothalamic GABAergic circuits that drive UCP1-dependent adipose thermogenesis, establishing a liver→brain→fat axis as the primary mechanism for GCGR-mediated energy expenditure and weight loss rather than appetite suppression.\",\n      \"evidence\": \"Chronic GCGR agonism in obese mice with metabolic cages, hypothalamic GABAergic manipulation, UCP1 quantification\",\n      \"pmids\": [\"41654017\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Afferent signal from liver to hypothalamus not identified\", \"Whether this axis operates in humans not established\", \"Relative contribution of direct hepatic vs. CNS-mediated effects not quantified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"β-arrestin recruitment to GCGR was shown to be phosphorylation-independent, contrasting sharply with GLP-1R and GIPR where C-tail phosphorylation is required — revealing receptor-specific desensitization mechanisms among closely related class B GPCRs.\",\n      \"evidence\": \"Mass spectrometry phosphosite identification, site-directed mutagenesis, β-arrestin recruitment and cAMP assays (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.03.10.642457\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Not peer-reviewed\", \"Structural basis for phosphorylation-independent β-arrestin engagement not determined\", \"In vivo consequences for receptor desensitization and trafficking not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions include the identity of the afferent signal linking hepatic GCGR activation to hypothalamic thermogenic circuits, the structural basis for phosphorylation-independent β-arrestin recruitment, whether G protein pre-coupling operates physiologically in native hepatocytes, and the long-term safety implications of GCGR-driven islet cell proliferation for dual-agonist therapeutics.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Liver-to-brain signal mediating thermogenesis unidentified\", \"No structure of GCGR–β-arrestin complex\", \"Physiological relevance of ligand-free G protein pre-coupling untested in primary cells\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 3, 12, 17]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [18, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 22, 30]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 17, 18, 24]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [4, 13, 14, 27]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GNA5\",\n      \"GNAI1\",\n      \"ARRB2\",\n      \"AC5\",\n      \"RACK1\",\n      \"CD9\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}